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The Runx1 transcription factor is a master regulator of hematopoiesis and 
myeloid transformation. Its function is tightly orchestrated by diverse and appropriate 
signaling events to regulate cell fate decision, including granulopoiesis. Src 
phosphorylated Runx1 at 5 tyrosine residues; Y260 located at the transactivation domain 
and the C-terminal tyrosine cluster Y375, Y378, Y379 and Y386 at the repression 
domain. Tyrosine phosphorylated Runx1 inhibits megakaryopoiesis and thymocyte 
development but its effect on granulopoiesis is yet to be reported.  
In luciferase reporter assay in HEK293T cells, Src tyrosine kinase synergized 
with wild-type (WT) Runx1 to increase its transactivation potency. Significant 
transactivation effect was also observed with Runx1 tyrosine (Y) to glutamate (E) or 
aspartate (D) phopho-mimetic mutant variants where the transactivity increased to about 
2-fold compared to Runx1-WT. Conversely, tyrosine (Y) to phenylalanine (F) phospho-
null mutant variants did not exhibit transactivity. Exogenous Runx1 and its C-terminal 
phospho-mimetic mutant variant induced the transcriptions of endogenous Cebpa and 
PU.1 in the 32Dcl3 myeloid progenitor cell line as well as their protein productions, but 
not with the phospho-null Runx1.  
At least two mechanisms contribute to the increased Runx1 activity upon tyrosine 
phosphorylation. Tyrosine phosphorylated Runx1 bound better to its consensus sequences 
as assessed in Gel Shift Assay, and to the endogenous Cebpα and PU.1 enhancers in 
Chromatin Immunoprecipitation Assay. In addition, after cycloheximide treatment, high 
levels of Runx1-5D and 4D protein expressions could sustain up to 8 hours while the 
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Runx1-5F and 4F proteins were degraded between 2-4 hours. The stability of the Runx1-
5D was associated with weaker interaction with ubiquitin and also its resistance to Cdh1-
mediated ubiquitin proteosomal degradation.  
Combining these observations, we propose that Runx1 phosphorylation by Src at 
the five tyrosine sites increase its transactivity, binding affinity and stability, and 
therefore promoting the induction of mRNA and protein expressions of Cebpa and PU.1, 
which are the crucial early differentiation biomarkers in myelopoiesis and granulopoiesis. 
Further investigations on the regulation of tyrosine phosphorylation on Runx1 will shed 
more insights on the molecular mechanisms underlying granulopoiesis and its 
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CHAPTER 1: BACKGROUND REVIEW OF RUNX1 
1.1 Runx1 is a master regulator in hematopoiesis 
All blood cell lineages originate from hematopoietic stem cells (HSCs). The 
development of lineage-committed blood cells from HSCs, and their subsequent 
maintenance in adulthood, is tightly coordinated to ensure the precisely timed 
manifestation of functionally mature blood cells in a tissue-specific and spatiotemporal 
manner. The biological events that regulate the hematopoiesis process include the 
acquisition or production of growth or differentiation cytokines or ligands, coupled with 
the activation of intrinsic lineage-specific transcription factors, such as the hematopoietic 
master regulator Runx1.  
The Runx1 gene was first isolated and cloned from the leukemic cells of acute 
myeloid leukemia (AML) patients who were diagnosed with chromosomal translocation 
t(8;21) (Miyoshi H, 1991). Runx1 encodes for the DNA-binding subunit of the 
heterodimeric core-binding factor (CBF) transcription factor family, and it is mainly 
expressed in hematopoietic cells (Heller PG, 2013; North TE, 2002). The region in 
Runx1 gene that encodes the conserved Runt DNA binding domain (DBD) is the 
mammalian homolog of the runt gene from Drosophila as both of their encoded amino 
acid sequences are 69% identical (Meyers S, 1993). Hence, Runx1 belongs to a family of 
transcriptional factor known as Runx in mammalian cells - the other two members are 
Runx2 and Runx3. In humans, the Runx1 gene is located at the chromosome 21q22.12, 
spans approximately 260 kilobases, and contains 12 exons. (Levanon D, 2001).  
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Diversity of Runx1 is contributed by transcriptions from two different promoter 
sites and alternative splicing (Miyoshi H, 1995). Therefore, DNA transcription can begin 
either at the proximal or distal promoter, which are 160 kilobases apart, giving rise to 
different Runx1 isomers. Runx1a and Runx1b are transcribed from the proximal 
promoter, whereas Runx1c is transcribed from the distal promoter (Heller PG, 2013). In 
addition, alternative splicing from the exons of Runx1 yield 12 different Runx1 cDNAs 
and at least three isomers of Runx1. Runx1a is a truncated spliced variant (250 amino 
acid) from exons 3 to 7a; Runx1b (453 amino acid) starts from exons 3 to 8; Runx1c is 
the full-length protein (480 amino acid) that includes exons 1 and 2 (Heller PG, 2012; 
Miyoshi H, 1995). Thus, exon 8 encoding the transactivation domain is absent in Runx1a 
but is still intact in Runx1b and Runx1c. 
Similar to the general structures of other transcription factors, Runx1 has two 
distinct domains – the DNA binding Runt domain (DBD), and the transactivation domain 
(TAD, Figure 2). The DNA binding Runt domain is located at the N-terminal region and 
facilitates its sequence-directed binding to target genes; it also mediates protein-protein 
interaction (Meyers S, 1993). The conformation of this binding domain is immunoglobin-
like and is related to the DNA binding domain of the tumor suppressor p53 (Milton HW, 
1999).  The central transactivation domain of Runx1 is responsible for the regulation of 
target gene activation and serves as a binding site for various transcriptional co-regulators 
(Bae SC 1994).  Located immediately adjacent to the transactivation domain is the C-
terminal repression domain (REP), which overlaps partially with the negative regulatory 
region for heterodimerization (NRHc) (Ito Y, 1999). Another conserved domain present 
in Runx1 is the pentapeptide VWRPY motif at the C-terminal end of the protein, which 
 
 3 
mediates Runx1 transcriptional repression (Nishimura M, 2004; Imai Y, 1998; Aronson 
BD, 1997).  The amino acid sequences of all three isomers of Runx1a, Runx1b and 
Runx1c are more than 90% homologous (Milton HW, 1999), suggesting that they use 
similar mechanisms in DNA-binding and heterodimerization.  
Several in vitro studies in transgenic mice implied that Runx1 plays crucial roles 
in the emergence of definitive hematopoiesis and long-term repopulating HSCs from 
hemogenic endothelium through the Notch signaling pathway  (North TE, 2002; Li C, 
2015). Conditional Runx1 excision in the vascular-endothelial-cadherin-positive mice 
endothelial cells revealed that Runx1 was required for the transition of endothelial cells 
to HSCs at E11.5, and that these emerging HSCs could engraft to adult mice (Chen MJ, 
2009). Homozygous Runx1 knock-out mouse embryos failed to develop fetal liver 
hematopoiesis and therefore died of extensive hemorrhage at midgestation by E12.5 
(Okuda T 1996), central system hemorrhages and necrosis (Wang Q, 1996). This embryo 
lethality in Runx1-deficient mice makes it challenging to study the function of Runx1 
during embryogenesis.  
After definitive hematopoiesis has occurred, Runx1 is dispensable in the 
maintenance of HSCs in adult hematopoiesis (Chen MJ, 2009; Ishikawa M 2004). 
Nonetheless, the loss of Runx1 is detrimental to the terminal maturation processes of 
several blood lineages. When Runx1 was conditionally deleted in the bone marrow of 
adult mice, granulocyte formation was perturbed while monocyte formation was 
increased (Guo H, 2012). Adult mice with Runx1-deficient bone marrow displayed a 30-
80% decline of megakaryocyte maturation, a block of DN2  (double negative) to DN3 
stage in T-lymphocytes development as well as inhibition of B-lymphocytes 
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differentiation. In addition, these mice showed expanded population of hematopoietic and 
myeloid progenitors with augmented replating capacity due to the partial block of 
myeloid cell differentiation (Ichikawa M, 2004). Consistent with those findings, Putz et 
al. also demonstrated that adult mice with conditional Runx1 deletions had smaller 
thymus with accumulation of immature DN lymphocytes, and, at longer latency, 
developed metastatic lymphoma, lymphocytopenia, thrombocytopenia and progressive 
splenomegaly (Putz G, 2006). These results revealed that the lack of Runx1 in adult mice 
severely impairs the structures and functions of hematopoietic progenitors and 
hematopoietic organs. 
In order for Runx1 to function physiologically, it has to form a heterodimeric 
complex at the DBD region with Core Binding Factor Subunit β (CBFβ), which itself is a 
non-DNA binding component. (Lu J, 1995). Mice with homozygous mutation of CBFβ 
exhibited identical hemorrhage phenotypes as in Runx1 knock-out mouse embryos, 
suggesting that CBFβ is essential for Runx1 function in vivo (Wang Q, 1996). The 
association of Runx1 to CBFβ increases the DNA binding affinity of Runx1 two to three 
fold more strongly than Runx1 alone (Bae SC, 1994). At the same time, interaction with 
CBFβ also relieves the intrinsic intramolecular inhibition effect of the Runx1 molecule 
(Gu T-L, 2000). Once Runx1 and CBFβ dimerize, they recognize the optimal consensus 
sequence “PuACCPuCA” or “TGT/cGGT” on the target DNA (Kamachi, 1990; Meyers S, 
1993).  
The Runx1 protein is also continuously degraded via the ubiquitin-proteasome 
pathway in murine myeloid progenitor cell lines 32Dcl3 and U937. Runx1-CBFβ 
heterodimer complex protects Runx1 from proteosomal degradation in murine myeloid 
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progenitor and embryonic cell lines (Huang G, 2001). Therefore, association of Runx1 to 
CBFβ not only ensures its transcription competence but also mediates its turnover in cells.  
The process of how dimerization of Runx1 and CBFβ is coordinated remains 
unclear although the respective locations of Runx1 and CBFβ have already been 
identified. Runx1 protein harbors the nuclear localization and nuclear matrix-targeting 
signal at its DNA binding Runt domain and therefore resides primarily in the cell nucleus 
(Kanno T 1998; Zeng C, 1997; Kanno T 1998; Lu J, 1995). In addition, Runx1 could be 
found in 2 distinct nuclear fractions, one that is tightly associated with the nuclear matrix 
where basal transcription complexes gather and the other is soluble in nucleoplasm 
(Biggs JR, 2005). When overexpressed in murine fibroblasts, CBFβ is found mainly in 
the cytoplasm compartment (Lu J, 1995). Further investigations of the interaction 
between Runx1 and CBFβ could uncover the underlying molecular mechanisms that 
regulate transcription in hematopoiesis. 
 
1.2 Genetic aberrations of Runx1 contribute to leukemogenesis 
The loss or dominant-negative suppression of Runx1 function due to various 
inactivating Runx1 somatic mutations have been commonly identified in patients 
afflicted with AML, spontaneous or radiation-induced myelodysplastic syndromes 
(MDS), myeloproliferative syndromes (MPS), familial platelet disorder (FPD) with 
predisposition to AML, and other hematological malignancies (Tang J-L, 2009; 
Zharlyganova D 2008; Fröhling S, 2005). All these diseases share a common 
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characteristic: that there is a combination of differentiation block and accumulation of 
myeloid precursors in the bone marrow. 
Despite the rare incidence of heritable mutations and the remarkably smaller 
number of mutations occurring in the AML genome compared to adult solid carcinomas 
(TCGA Research Network 2013, Welch 2012), Runx1 is a frequent mutation target in the 
founding clones obtained from human AML patients (Ding 2012). The most prevalent 
form of mutation identified is the RUNX1-RUNX1T1 or t(8;21)(q22;q22) chromosomal 
translocation that was found in 9%-30% of patients diagnosed with AML-M2, according 
to the French-American-British (FAB) classification (Mrózek K, 2004; Ichikawa M, 
2004; Grimwade D, 2001). Other chromosomal translocations involving Runx1 are 
t(16;21)(q24;q21), t(3:21)(q26;q22), and t(12;21)(p13;q22), which generate RUNX1-
MTG16, RUNX1-EVI1 (in chronic myelogenous leukemia), and TEL-RUNX1 (in acute 
lymphoblastic leukemia) fusion proteins, respectively. These recurrent reciprocal 
translocations produce dominant-negative Runx1, which interferes with the function of 
the normal Runx1 protein encoded by the other Runx1 allele, and therefore blocks 
myeloid progenitor cell differentiation, and affects cell proliferation, apoptosis, self-
renewal and survival, thereby contributing to leukemogenesis (Hayashi Y, 2000).  
Giphart-Gassler’s group reported the first case of total homozygous loss of Runx1 
in humans, which is associated with AML-M0 patients (Silva FPG, 2003). Heterozygous 
loss-of-function mutations, however, have been commonly identified, and they consist of 
nonsense mutations, missense mutations, frameshifts, intragenic insertions or deletions, 
and amplifications (Mendler JH, 2012, Silva FPG, 2003, Roumier C, 2003; Mikhail FM, 
2002). The somatic point mutations cluster in the gene region of Runx1 coding for the 
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binding surface of the DNA binding Runt domain (DBD), therefore abolishing its DNA 
binding ability, destabilizing its 3-dimensional structure or disrupting its 
heterodimerization competency to CBFβ. Sporadic Runx1 point mutations are reported in 
16% of AML patients with normal karyotype (Mendler JH, 2012), 21.5% in AML-M0 
subtype (Roumier C, 2003), 8% of MDS myeloblastic leukemia patients (Osato 1999), 
28% of MDS/AML, and 65% of congenital neutropenia (Skokowa J, 2014). 
Amplifications of Runx1 were predominantly identified in children with ALL (Roumier 
C, 2003). 
Chromosomal translocations and heterozygous point mutations or deletions of 
Runx1 are also underlying causes of Runx1 loss of heterozygosity (LOH) and 
haploinsufficency (Goyama S, 2015). The reduced dosage of Runx1 due to monoallelic 
germline mutation impairs the maturation processes of myeloid progenitor cells, and 
therefore predisposes individuals to various blood diseases, for example in MDS with 
propensity towards AML (MDS/AML). This observation is further enhanced by the 
myeloid-specific leukemia occurred in the BXH2-Runx1+/- murine model established by 
Ito’s group that recapitulates symptoms in human MDS/AML (Yamashita 2005). In 
another study, lineage-negative bone marrow of Runx1-haploinsufficency mice was 
extensively proliferative and allowed a limited level of lineage commitment but was 
poorly differentiated in response to differentiation cytokine (Ng KP, 2013).   The 
myeloproliferative characteristic could be the consequence of the upregulated Bcl-2 pro-
survival gene by the normal Runx1 gene (Goyama S, 2013). Scott’s group proposed that 
some cell types could be more sensitive and susceptible to the reduced dosage of Runx1, 
as the amount of Runx1 required for their normal activity varied (Michaud J, 2008). 
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Milton HW et al. pointed out that it is necessary to evaluate the functionality of the 
unaffected Runx1 allele so that any biochemical discrepancies between the mutant and 
normal Runx1 can be resolved to rescue the haploinsufficency phenotype. This approach 
could lead to the development of alternative therapies for AML patients (Milton HW, 
1999). 
Current consensus shows that single Runx1 mutation alone is insufficient or not 
solely responsible for leukemogenesis. Song et al. observed that the RUNX1-RUNX1T1 
genetic alteration could be identified in bone marrow, peripheral blood and cord blood 
samples of healthy individuals, reinforcing this consensus (Song J, 2011). Presence of 
this RUNX1-RUNX1T1 translocation itself could pose a higher risk for leukemic 
transformation, and other second mutations during adult hematopoiesis predisposes an 
individual to leukemia. Hence, Runx1 has been characterized as a classic tumor 
suppressor gene (Silva FPG, 2003). In addition, RUNX1-RUNX1T1 fusion protein 
probably also contributed to the initiation of AML, as the amount of somatic mutations 
was higher in normal karyotype AML compared to RUNX1-RUNX1T1 in de novo AML 
patients (Kihara R, 2014). 
Recent transgenic mouse models also confirmed that the expression of single 
Runx1 mutation is insufficient to cause AML. For example, Runx1 knock-out or 
RUNX1-RUNX1T1 knock-in mouse models had restricted transformation capacity and 
did not develop spontaneous leukemia (Ichikawa M, 2004; Rhoades KL, 2000) until 
cooperating mutations that altered the growth signaling pathway were introduced 
(Higuchi M, 2002).  
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These additional cooperating genetic alterations other than Runx1 are widely 
known to participate in the full malignant cell transformation of all types of leukemia. 
The expanded myeloid progenitor pool in Runx1-null bone marrow is prone to acquire 
these “second hits” activating mutations, in which they cooperate with the initiating 
Runx1 mutations to confer a myeloproliferative advantage, escalating the disease to full-
blown leukemia. A recent microarray-based gene profile study revealed that RUNX1-
RUNX1T1 could trigger the base excision repair pathway, which is specific in restoring 
point mutations (Michaud J, 2008). Therefore, abnormality in Runx1 function closely 
corresponds with an increased rate of mutations, generating pools of mutated progenitor 
cells. 
Concurrent mutations of the Type III Receptor Tyrosine Kinase (RTK) genes, 
such as FLT3 and c-KIT usually accompany the manifestation of leukemia in 40% of 
human leukemia cases (Yamashita N, 2005). N-RAS mutations were also identified in 
11% of the de novo AML patients (Gustafson SA, 2009). AML patients who are 
diagnosed with exclusive RUNX1-RUNX1T1 translocations have a favorable prognostic 
outcome, while the presence of additional mutations of Flt3 or cKit ameliorates their 
favorable prognosis (Ishikawa 2009). Concurrent and multiple genome editing in primary 
HSCs through the CRISPR-Cas9 method provided additional evidences that the loss of 
Runx1 could trigger proliferative advantage in heterozygous FLT3-ITD expressing HSCs 
in vivo, therefore resulting in a biased growth of myeloid lineage (Heckl D, 2014).  
When mutation in tyrosine kinase gene is not identified in some cases of AML, 
there may be a possibility that mutation in protein tyrosine phosphatases or cytokine 
receptors could be an alternative (Welch JS, 2012). In congenital neutropenia patients 
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with high risk of MDS/AML, mutations in the CSF3R gene that encodes the G-CSF 
receptor were frequently found in combination with Runx1 mutations, implicating their 
cooperative participation in leukemia progression (Skokowa J, 2014). 
 
1.3 Downstream transcriptional targets of Runx1 in granulopoiesis 
Numerous findings in RUNX1-RUNX1T1 clinical cases and transgenic mice 
models suggest that disruption of Runx1 inhibits the maturation of granulocytes from 
myeloid progenitors (Ng KP, 2013; Gaidzik VI, 2011; Tokita K, 2007; Vradii D, 2005; 
Lam K, 2004; Pabst T, 2001; Kohzaki H, 1999). These findings imply that the 
downstream transcriptional program that governs granulopoiesis in vivo is perturbed 
when Runx1 activity is diminished in leukemia (Rosmarin AG, 2005).  
A comprehensive microarray analysis of human bone marrow demonstrated that 
CCAAT/enhancer binding protein α (C/EBPα) is one of the approximately 11 thousand 
genes involved in the complete granulocyte differentiation from the progenitor stage 
(Theilgaard-Mönch K, 2005). Hong et al. reported that Cebpα transcription was down-
regulated in lineage-negative marrow cells and progenitors when Runx1 was dominantly 
inhibited or deleted in murine bone marrow. Introduction of exogenous Runx1 induced 
Cebpα transcription, whereas the expression of exogenous C/EBPα in these Runx1-
deleted marrow cells reversed the differentiation block and rescued granulocyte 
formation. Furthermore, Cebpα mRNA expression induced by Runx1 in the presence of 
the translational inhibitor cycloheximide was detected, which strongly indicates that 
C/EBPα is a direct downstream molecular target of Runx1 (Hong G, 2012). A 
 
 11 
comprehensive review of Runx1 studies also described C/EBPα as a critical transcription 
factor specifically activated for the early phase of granulocyte differentiation from 
myeloid progenitors (Friedman AD, 2002). 
Down-modulation of C/EBPα was apparent exclusively in AML patients 
diagnosed with CBF-disrupted AML (i.e. RUNX1-RUNX1T1 and CBFβ-SMMHC) 
compared to other AML subtypes (Cilloni D, 2003). In clinical samples of RUNX1-
RUNX1T1 patients, the protein expression of C/EBPα was undetectable whereas the 
mRNA level of Cebpa gene was 8-fold lower (Pabst T, 2001). In addition, the expression 
and DNA binding ability of C/EBPα was suppressed in Cos7 cells and monocytic 
progenitor U937 carrying the RUNX1-RUNX1T1 chimeric gene (Tokita K, 2007; Pabst 
T, 2001). Reduced expressions of Cebpa were also detected in AML patients who had 
somatic Runx1 point mutations with normal karyotype (Mendler JH, 2012). Similarly, a 
gene expression microarray analysis in Germany demonstrated that expression of Cebpa 
was significantly downregulated in Runx1-mutated AML patients (Grossman V, 2012). 
PU.1 is another molecular target of Runx1 that is necessary for normal myeloid 
differentiation, especially at the late maturation stage (Huang G, 2008; Friedman AD, 
2002). In AML patients or Kasumi-1 cells harboring the RUNX1-RUNX1T1 
chromosomal aberration, PU.1 activity was diminished, and mice with homozygous loss 
of PU.1 did not develop mature myeloid cells (Vangala RK, 2003). As shown in a 
previous study on Runx1 deficient zebrafish embryos, Runx1 regulated PU.1 via a 
negative feedback loop, favoring granulocyte differentiation and neutrophil production 
(Jin H, 2012).  Conditional deletion of Runx1 in adult mice also showed a down-
regulation of Cebpa and PU.1 RNA level in its lineage-negative bone marrow cells and 
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granulocyte-monocyte progenitors, although it caused a significant skewed differentiation 
of monocytes compared to that of granulocytes. Furthermore, the reintroduction of 
exogenous Runx1 in the Runx1 deficient bone marrow cells rescued the expression of 
C/EBPα and granulocyte formation (Guo H, 2012). These observations were consistent 
with an earlier finding that PU.1 expression was down regulated in Runx1 knock-out 
mice, therefore inhibiting granulocytic development (Huang G, 2008).   
C/EBPα is the founder member of the leucine zipper transcription factor family, 
whereas PU.1 belongs to the ets transcription factor family. They are non-redundant in 
their roles in myeloid cell development. Runx1 directly regulates C/EBPα and PU.1 to 
activate myeloid lineage maturation by interacting with their promoters and enhancers. 
Runx1 binds to conserved DNA sequences in the Cebpa promoter and the +37kb 
enhancer (Cooper S, 2015; Guo H, 2012). The regulation of Pu.1 transcription by Runx1 
occurs via its -14kb enhancer (Huang G, 2008).   
 
1.4 Post-translational modifications of Runx1 facilitate recruitment, 
assembly and interaction with co-regulators to affect Runx1 function 
and myeloid development 
In addition to differential transcription, alternative splicing, and the generation of 
different isoforms, the diverse functions of Runx1 are further expanded by its 
combinations of multiple post-translational modifications (PTMs) to fine-tune the precise 
modulation of Runx1 activities in spatiotemporal and lineage-specific conditions. Among 
the common types of PTM identified on Runx1 are phosphorylation, ubiquitination, 
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acetylation, and methylation. The amino acid residues that are being modified are 
conserved across the Runx proteins (Goyama 2014), implicating that the PTM 
mechanisms are shared among the Runx family members.  
PTM facilitates the assembly of various downstream transcription factors or 
epigenetic components on Runx1. Multiple molecular factors usually bind to Runx1, 
either directly or indirectly, which subsequently affect cell fate and lineage-specific gene 
expressions (Prange KHM, 2014). Therefore, PTM of Runx1 could either positively or 
negatively impact the development of hematopoietic stem/progenitor cells depending on 
the types of complexes that it forms with other molecular co-regulators. For example, 
Runx1 promotes the progression of G1-S and S-G2/M cell cycle in myeloid progenitors 
through the serine/threonine phosphorylation by Cyclin-dependent kinase 1 (Cdk1)/cyclin 
B, Cdk6/cyclin D3 and Extracellular-Regulated Kinase (ERK) and therefore favoring cell 
proliferation (Zhang L, 2008). At the same time, association of cyclin D or Cdk6 to 
Runx1 outcompetes the heterodimerization of Runx1-CBFβ, therefore reducing the DNA 
binding affinity and transactivation of Runx1, subsequently down-regulating PU.1 and 
abrogating terminal myeloid differentiation but sustaining myeloid progenitor 
proliferation in vitro and in vivo (Fujimoto T, 2007; Peterson LF, 2005). 
Phosphorylation may be required for the normal transcriptional process and 
proteosomal degradation. As mentioned earlier, Runx1 is constantly degraded in cells. 
Loss of serine or threonine phosphorylation at S276, S293, S303 and T300 reduced 
Runx1 transactivation, caused the accumulation of ubiquitinylated-Runx1, stabilized the 
protein and retained it at the nuclear matrix (Biggs JR, 2005). A follow-up study further 
revealed that the phosphorylation of these serine and threonine residues were catalyzed 
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by Cdk1/cyclin B and Cdk2/cyclin A, which subsequently mediated Runx1 degradation 
by Cdc20 and Cdh1 in the Anaphase Promoting Complex (APC)   (Biggs JR, 2006). 
Mutation of S249 and S266 to alanine also prevented ERK-dependent phosphorylation, 
which led to its firm association with nuclear matrix mediated by mSin3A corepressor, 
thereby increasing its stability, protecting it from proteosomal-mediated degradation as 
well as abolishing its transactivity  (Imai Y, 2004).   
Similar to other transcription factors, Runx1 also modulates target gene 
expression through recruitment of chromatin modifiers, such as histone acetylases 
(HATs) or histone deacetylases (HDACs). Phosphorylation of S48, S303 and S424 by 
Cdk1 or Cdk6 enhanced the transactivation potential of Runx1 and triggered cell 
proliferation in Ba/F3 myeloid cells and lineage negative murine marrow progenitor cells, 
partly due to reduced interaction with HDAC1 and HDAC3 (Hong G, 2010; Zhang L, 
2008). Recruitment of p300 and CREB binding protein (CBP) through homeodomain-
interacting protein kinase-1/2 (HIPK1/2)-mediated phosphorylation on S249 and S276 
also corresponds to increased level of Runx1 transactivation and induction of myeloid 
cell differentiation (Aikawa Y, 2006; Kitabayashi I, 1998). After binding to the C-
terminal region of Runx1, co-activator p300 acetylates Runx1 on K24 and K43, further 
enhancing the DNA binding and transcriptional activity of Runx1 (Yamaguchi Y, 2004; 
Kitabayashi I, 1998).  
Methylation is usually linked with suppression of gene expression or protein 
function. However, methylation of R206 and R210 by arginine methyltransferase, 
PRMT1, removes the association of mSin3A co-repressor to Runx1, thus enhancing 
Runx1 transcriptional activity (Zhao X, 2008). The suppression of Runx1 activity is 
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achieved by PRMT4 methylation on R223, which promotes the binding of co-repressors 
onto Runx1 and eventually abrogates myeloid cell differentiation (Vu LP, 2013). 
 
1.5 Tyrosine phosphorylation of Runx1 by protein tyrosine   kinases in 
myeloid progenitor cells 
Cytokines can instruct cell fate decision and influence lineage choices. When 
myeloid progenitors are exposed to Granulocyte Colony Stimulating Factor (G-CSF) 
cytokine or other differentiation ligands, a cascade of signal transduction events is 
activated through the G-CSF receptor (G-CSFR) or other cognate receptors (Ward AC, 
1999). Facilitated by combinations of various lineage-specific molecular transducers and 
transcription factors, the differentiation signals eventually steer the myeloid progenitors 
into the terminal granulocytic differentiation process. Tyrosine modifications on these 
molecular transducers, for example, phosphorylation, mediate their activation and 
effective signal propagation from the cell membrane into the cellular compartments. 
Tyrosine phosphorylation of Runx1 by Src-family tyrosine kinases (SFK) was 
recently identified (Neel BG, 2012; Huang H, 2012). In murine and human 
megakaryoblast and T-lymphoblast cells, tyrosine phosphorylation of Runx1 impaired 
their commitment into mature platelets and CD8+ T-lymphocytes. Inhibition of SFK 
activities, on the contrary, restored the maturation processes of megakaryocyte and CD8+ 
T-lymphocytes. Therefore, Runx1 tyrosine phosphorylation negatively regulates 
megakaryopoiesis and thymocyte development. The exact members of SFK that were 
responsible for tyrosine phosphorylation of Runx1 were not addressed in this report, but 
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the subset of tyrosine residues that were modified by SFK were identified by mass-
spectrometry and mutational analysis. These tyrosines are mostly located at the REP 
domain of Runx1 (Huang H, 2012).  
In that same article, the authors also demonstrated that the non-receptor tyrosine 
phosphatase – Src homology region 2 domain-containing phosphatase 2 (SHP2), 
physically binds to Runx1 and dephosphorylates one or more Runx1 tyrosine residues, 
although their identity has yet to be determined  (Huang H, 2012). When Ba/F3 myeloid 
progenitors are stimulated by G-CSF, SHP2 is phosphorylated and results in preferential 
activation of granulopoiesis. Inhibition of SHP2 activity reduced the formation of colony-
forming-unit-granulocytes (CFU-Gs) from lineage-negative murine bone marrow 
mononuclear cells (Jack GD, 2009). In addition, knock-down of SHP2 expression in 
myeloid progenitors and in murine marrow cells also down-regulated Cebpα and 
repressed granulopoiesis; the reduction in Cebpα expression was restored by exogenous 
Runx1 (Zhang L, 2011).  Besides acting on Runx1 or affecting granulocyte 
differentiation via C/EBPα, SHP2 also participated in the G-CSF signaling pathway by 
mediating the activation of Src kinase Lyn in Ba/F3 cells after Lyn binds to the G-CSFR 
(Futami M, 2011).  Together, these findings together indicate that Runx1 is the key 
molecular component at the intersection of the G-CSF signaling pathway in 
hematopoietic progenitors cells that is regulated by SFK-SHP2 activities. 
Several other protein tyrosine kinases have also been identified in myeloid 
progenitor cells. Among them are Hck, Lyn, Fgr, Syk and Fes, which are all major 
members of the SRC family kinase (SFK) (Corey-PNAS 1994; Ward-BBRC 1998). 
Although Hck, Lyn and Fgr are found to be highly expressed in terminally differentiated 
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myeloid cells, myeloid progenitors lacking these three tyrosine kinases did not affect the 
terminal granulocyte differentiation and showed normal neutrophil formation; conversely, 
the G-CSF induced proliferation and myeloid progenitor production was greatly 
enhanced (Mermel, 2006; Perlmutter RM, 1989). An early article revealed an opposite 
effect of Hck, in which the overexpression of activated Hck in 32Dcl3 myeloid 
progenitor interfered with granulocytic differentiation (English BK, 1996). Fes facilitated 
the terminal differentiation of granulocytes and monocytes in a lineage-specific manner 
as well as in the absence of differentiation cytokines, and concomitantly activated the 
Cebpα and PU.1 during these differentiation processes, respectively (Kim J, 2004; Kim J, 
2003).  
 Jak2, another cytoplasmic non-receptor tyrosine kinase known as “Just another 
kinase 2” promotes mIL3-induced survival of myeloid progenitor cells through the 
activation of ERK2 (Chaturvedi P, 1998). Activation of Jak2 is frequently linked to 
activation of STAT3 (Signal Transducer and Activator of Transcription 3), as both of 
these intracellular signaling molecules are the early responders in the G-CSF signaling 
cascade (Jack GD, 2009; Tian S-S, 1996). STAT3 itself is a main activation target of G-
CSF receptor and is required in the steady-state homeostasis of neutrophil production and 
in the acute mobilization of neutrophils into circulating blood (Panopoulos A, 2006; Lee 
C, 2002). Tyrosine phosphorylation and activation of Jak2 and STAT3 were detected in 
terminally differentiated human neutrophils following GM-CSF stimulation and also in 
the proliferating G-CSF receptor expressing Ba/F3 myeloid progenitors following G-CSF 
stimulation (Al-Shami A, 1998; Avalos BR, 1997). Activating mutation of Jak2, 
Jak2(V617F) is implicated in myeloproliferative neoplasms, where it was identified in the 
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granulocytes, erythroid and myeloid precursors (Baxter EJ, 2005). Interestingly, the 
constitutively augmented kinase activity of Jak2(V617F) also caused the up-regulation of 
PU.1 expression (Irino T, 2011).  Together, these reports illustrated the complex role 
played by Jak2 as it could contribute to both myeloid progenitor proliferation and 
differentiation, although its exact mechanism in these developments requires more 
investigation. 
Despite the extensive studies published on the functions of tyrosine kinases in 
normal hematopoietic systems and in hematological malignancies, the ability of Src, Lyn, 
Syk, Hck, Fes or Jak2 to phosphorylate Runx1 to directly affect its intrinsic 
transactivation potential is still unknown and therefore is the focus of this study. 
 
1.6 Objectives of study 
In this study, the contribution of Runx1 tyrosine phosphorylation to the regulation 
of granulopoiesis and its role in the G-CSF signaling pathway is characterized. Given that 
SHP2 and Runx1 activate both Cebpα mRNA and protein expression to promote 
granulocyte differentiation, it was logical to speculate that tyrosine modification on 
Runx1 might be one of the many mechanisms to regulate C/EBPα activity.  
Furthermore, SRC phosphorylates and SHP2 dephosphorylates tyrosine residues 
on Runx1, and SHP2 mediates the activation of SRC in the G-CSF signaling pathway. 
These findings imply that there is a dynamic, functional and multimeric interaction 
between SHP2, SRC and Runx1. This leaves open the question as to which 
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phosphorylated form of Runx1 mediates transcription activation and induction of 
C/EBPα.  
We are especially interested in the biological effects of Runx1 phosphorylation 
during granulocyte differentiation. The inhibition of megakaryopoiesis and thymocyte 
development by non-phosphorylated Runx1 in adult mice bone marrow, demonstrated by 
Cantor’s group, prompted us to evaluate the role of Runx1 phosphorylation in myeloid 
progenitors and verify the sequence of events proposed in our model of the G-CSF 
signaling pathway in granulopoiesis (Figure 1).  
In order to achieve these aims, the design of this study is divided into 2 parts: 
(1) Determine whether the tyrosine phosphorylated or the non-
phosphorylated Runx1 shows transactivity potential and promote 
induction C/EBPα 
(2) Investigate the mechanisms utilized by tyrosine phosphorylated or 
non-phosphorylated Runx1 to regulate its transactivity potential and 
activation of C/EBPα 





G-CSF  SHP2  SRC  Runx1  C/EBPα  Granulopoiesis 
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CHAPTER 2: MATERIALS & METHODS 
2.1 Tissue culture 
Human embryonic kidney HEK293T cells (ATCC) were cultured in Dulbecco’s 
modified Eagle medium (DMEM; Life Technologies) supplemented with 10% heat-
inactivated fetal bovine serum (FBS; Hyclone). Lipofectamine® 2000 (Invitrogen) was 
used for transient transfection in HEK293T cells. Murine myeloid progenitors 32Dcl3 
cells (Valtieri M, 1987) were maintained in Iscove’s modified Dulbecco’s medium 
(IMDM; Life Technologies) supplemented with 10% of heat-inactivated FBS (Hyclone), 
1X Penicillin-Streptomycin (Life Technologies) and 1 ng/ml of murine interleukin 3 
(IL3; Peprotech). To initiate differentiation, 32Dcl3 cells were washed twice in 1X 
phosphate-buffered saline before transferring to IMDM with 20 ng/ml GCSF (Amgen). 
For stable retroviral transduction, the 32Dcl3 cells were subjected to electroporation 
using the Amaxa Nucleofector system (Lonza) or to retroviral RetroNectin system 
(Takada).  Subclones were screened through limiting dilution in 0.2 µM of puromycin or 
1.2 mg/ml of neomycin (Sigma-Aldrich). Protein induction was made through addition of 
20 ng/ul 4’-hydroxytamoxifen into IMDM. For suppression of kinase activity, PP2 kinase 
inhibitor was provided at 20 μM final concentration. 32Dcl3 stable clone (77-10) carrying 







The gene encoding the mouse Runx1b isoform and its mutant variants 5F, 5D, 
and 2F variants were cloned into pcDNA3 (CMV). Generation of the 4F, 4D, 1F, and 1D 
mutant variants was done through restriction digestion of the BamHI site that separates 
the Y260 from the other 4 residues at the C’-terminal tyrosine cluster.  The 2F*, 2E, 2E* 
mutant variants were synthesized (Blue Heron) and were ligated to the 584bp BamHI-
EcoRI fragments. pEF1α-birA, pEF1α-birA-FLAGBio-Runx1 and its tyrosine mutants 
were previously described (Huang H, 2012). The pBabePuro-Runx1(4F)-ER(T) and 
pBabePuro-Runx1(4E)-ER(T) were made from pBabePuro-Runx1-ER(T) by replacing 
the 589bp BamHI-MluI fragments. CBF4-TK-Luc, CMV-βGal, pCEFL-Src(E381G), 
CMV-CBFβ, CMV-HA-Cdc20, CMV-HA-Cdh1 were previously reported (Zhang L, 
2008; Bigg JR, 2006; Bjorge JD, 1995; Ogawa E, 1993). CMV-HA-Cdc20, CMV-HA-
Cdh1, CMV-HA-Ubiquitin was acquired from commercial source (Addgene). 
pBabePuro-Src-ER(T) was generated by linking the DNA encoding the ERα ligand-
binding domain C-terminal to the DNA of Src(E381G) in pBabePuro retroviral 
expression plasmid. 
 
2.3 Luciferase Reporter Assay 
Ten-thousand HEK293T cells were plated into each well of the 24 well cell 
culture dish, and was incubated overnight in the 5% CO2 incubator. Five ng of pcDNA3-
mRunx1b plasmid DNA was co-transfected with 2 ng of beta-galactosidase and minimal-
TK-Luc, either with or without 40 ng of activated Src. After 48 hours of transfection, the 
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cells were lysed and the luciferase and beta-galactosidase activity were then measured 
using the luminometer. 
 
2.4 mRNA Expression and Quantitative PCR 
Total mRNA was extracted with the NucleoSpin RNA II kit (Machery-Nagel) 
following the manufacturer’s instructions. First-strand synthesis of cDNA was prepared 
at 42oC for 1 hour using the ImProm-II™ Reverse Transcription System (Promega) and 
the provided oligo dT primers. Quantitative polymerase chain reaction (PCR) was carried 
out using 5 ng of cDNA product, iQ SYBR Green (Bio-Rad), and primer pairs targeting 
Runx1, Cebpα, PU.1, or Actin. Details of oligonucleotides (Sigma-Aldrich) are listed in 
Table 1. 















Pu.1 enhF CTGGTGGCAAGAGCGTTTC 
Pu.1 enhR CCACATCGGCAGCAGCAAG 
Actin-1500F GGGAAAGTTCTCTCAGGGTTGG 
Actin-1500R TGCTGTGAACTGGAAACACACC 
Table 1: Sequences of oligonucleotides used for quantitative PCR. 
 
2.5 Protein Expression and Western Blots 
Whole cell lysates were prepared using the Laemmli sample buffer while the 
nuclear extracts were prepared using 400 mM of NaCl. Whole cell lysates or nuclear 
extracts were resolved in SDS-PAGE and then transferred to a PVDF membrane that was 
pre-moistened with methanol. The membrane was probed with primary antibody 
overnight at 4oC, followed by incubation for 1 hour with secondary antibodies that were 
conjugated with HRP. Primary antibodies used were RUNX1 (Active Motif), C/EBPα 
(14AA), PU.1 (D-19), HA (Y-11), ERα (MC-20), or Lamin B (M-20; Santa Cruz), HA 
(16B12; BioLegend), P-Tyr (4G10, Millipore), HDAC1 (ab7028) or HDAC3 (3G6; 
Abcam), FLAG (M2) or β-actin (AC-15; Sigma), GAPDH (14C10; Cell Signaling), anti-
V5 (Invitrogen), CBFβ (Cao W, 1997). Protein bands were then visualized using 




2.6 Electrophoretic Mobility Shift Assay 
Nuclear extracts from transfected 293T cells were prepared in 400 mM NaCl. 
Protein products were also obtained using the rabbit reticulocyte lysate in the In vitro 
TnT® Coupled Transcription Translational System (IVT; Promega), with and without 25 
µM of MG132 (Sigma). Equal amount from each nuclear extract or IVT sample was 
subjected to electrophoretic mobility shift assay as described (Guo H, 2012). The 
oligonucleotide used was derived from the Runx1 binding site on the myeloperoxidase 
(MPO) promoter and was radio-labeled with 0.0032 mM of αP32-dCTP. The 
oligonucleotide pairs are: Runx1MPO-T (5’-CTAGACTGACCATTAACCACAACCAG 
TTG-3’) and Runx1MPO-B (5’-CTAGCAACTGGTTGTGGTTAATGGTCAGT-3’). 
The protein-oligo complexes were transferred from the gel onto a PVDF membrane. 
Then, the radioactive signals were exposed to and detected using autoradiography. 
 
2.7 Chromatin Immunoprecipitation (ChIP) Assay 
Total cell extracts from 1 million 32Dcl3 stable cells expressing Runx1 or its 
variants were subjected to ChIP assay with 2 mg ER or normal rabbit IgG. Next, 
quantitative PCR was performed using 0.5 µL precipitated genomic DNAs and 1 µg/µL 
of the following oligonucleotide pairs: Cebpα-enh and Cebpα-enhR3-F, Cebpα-2500F 





2.8 Protein Immunoprecipitation 
Whole cell lysates of transfected HEK293T cells were extracted and then were 
measured and equalized using the Bradford assay. Coimmunoprecipitation (Co-IP) of 
Runx1 or its variants was carried out using HA-Ubiquitin. The co-IP buffer consisted of 
20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.2% Nonidet P-40, 0.2% 
Triton X-100, 0.2% sodium deoxycholate, 10% (w/v) glycerol, 1 mM NaF, 1 mM 
Na3VO4, 1 mM PMSF, and 1X protease inhibitor cocktail (Sigma) as described 
previously (Guo H, 2011). Tyrosine phosphorylation of Runx1 was assessed with similar 
IP procedures using anti-ERα in whole cell lysates of 32Dcl3 stable clones expressing 
Runx1-ER(T) or its variants, which were pre-treated with 1.25 mM Na3VO4 for 15 
minutes to inhibit activity of endogenous protein tyrosine phosphatases. Interactions 
between Runx1 or its variants and CBFβ were demonstrated using HEK293T cells co-
expressing pEF1α-FLAGBio-Runx1 and pEF1α-birA. The protein complexes were 
pulled-down with streptavidin agarose (Novex®). All immunoprecipant was analyzed 
with Western Blot. 
 
2.9 Statistical Analysis 
Means and standard error are indicated in figures 2, 3 5 and 8, and comparisons 
for significance were accessed using the Student T-test. Band intensities on Western Blot 




CHAPTER 3: RESULTS 
3.1 Tyrosine phosphorylation of Runx1 increases transactivation 
There are a total of 15 tyrosine sites on Runx1, 10 of which are conserved (Huang 
H, 2012). The tyrosine residues that are modified by Src are Y260 in the transactivation 
domain (TAD) and Y375, Y378, Y379 and Y386 in the C-terminal repression domain 
(REP) (Huang H, 2012; Figure 2A). Tyrosine residues (Y) are switched to phenylalanine 
(F) to confer a phospho-null phenotype.  On the other hand, Y residues are replaced by 
glutamate (E) or aspartate (D) to mimic the constitutive phosphorylation state of Runx1 
by Src. Several tyrosine mutant variants were generated to study the effect of tyrosine 
phosphorylation on Runx1 transactivation and DNA binding. The combinations of the 
mutated tyrosine residues are listed in Figure 2A, bottom panel. 
pCMV-Runx1 and its variant mutants of equal amounts were co-transfected with 
CBF4-TK-Luc and CMV-βGal in the HEK293T cells. The transfected cells were used to 
investigate the Runx1 protein expression as well as for the luciferase reporter assay. 
CBF4-TK-Luc contains four repeats of Runx1 consensus sites, located at the upstream of 
a minimal thymidine kinase promoter and luciferase cDNA (Figure 2B). When Runx1 
protein binds to CBF4, the transcription of the luciferase gene will be activated, which is 
driven by the TK promoter. Fold–activation changes were reported as the ratio of 
luciferin signals to the β-galactosidase signals after normalizing to the empty CMV 
vector control. The transactivity of Runx1-WT was 5-fold higher than the CMV vector, 
while the transactivity of 5F and 4F was only about 2-fold. Transactivity of 1F was 
similar to that of WT. In contrast, 5D showed the highest transactivity at about 10-fold, 
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followed by 4D and 1D (Figure 3A, top). The distinctive levels of transactivation in these 
mutant variants reflected that the phosphorylation of each tyrosine residue has a different 
impact on Runx1 transactivity. 
To map out which tyrosine residues are critical in Runx1 transactivity, a similar 
luciferase reporter assay was repeated using other Runx1 mutant variants, 2F*, 2E*, 2F, 
2E, and different mutants with single a tyrosine mutation (Figure 3B, left). Again, 2F* 
and 2F had low transactivity, while 2E* and 2E displayed up to an 8-fold increase in 
transactivity. The other single F and 2F mutant variants were expressed in the pEF1a 
vector. Although their protein expression was similar to the Runx1-WT in Western Blot, 
the transactivation of 2F again showed reduced transactivation while the single F mutant 
variants manifested similar transactivity as that of WT (Figure 3B, right). This 
observation further suggests that at least 2 tyrosine sites at the C-terminal REP are 
required to affect transactivity of Runx1.  
It was noted that the total protein expression of 5D and 4D was higher than Runx1 
and the other variants, partly contributing to the higher transactivity in the luciferase 
reporter assay (Figure 3A, bottom). The migration of the Runx1 bands of 5D and 4D 
were also slightly retarded than those of Runx1 and F mutant variants, which reflected 
their higher negative charges. However, the higher protein expression of 5F, 4F, 2F* and 
2F did not alter the reduced transactivity (Figures 3A and 3B, bottom), therefore, one 




When pCEFL-Src(E381G) was co-expressed with Runx1-WT to assess the effect 
of cooperation, there was a significant synergistic effect observed in the luciferase 
reporter assay. Runx1 synergizes with Src to markedly increase the transactivity to about 
31X, or at 7.4X higher than Runx1 alone. 5F displayed a minimal effect when combined 
with Src and only showed a mere 2.6-fold activation, which was similar to the activity of 
Src alone (Figure 4A). The Runx1-WT expression assessed by Western Blot also 
exhibited a significant increase in the presence of Src and also migrated more slowly due 
to the effect of phosphorylation. The 5F protein band, however, only showed minimal 
increase in expression when co-expressed with Src. Fes and Jak2 are another two major 
members of non-receptor tyrosine kinases preferentially expressed in myeloid cells that 
regulate myeloid gene expression during granulopoiesis. Interestingly, in the luciferase 
reporter assay, Fes minimally increased Runx1 transactivity to only 6.2X but 
Jak2(V617F) did not increase Runx1 transactivity (Figure 4B). These results not only 
highlight that the five tyrosine residues are the specific substrates for Src kinase and are 
important for Runx1 transactivation activity but also give a representation of the 
maximum transactivity effect of Runx1 when phosphorylated in vitro, in which this effect 
was observed in the luciferase reporter assay using 5D tyrosine mutant.  
Runx1 interacts with a cofactor called CBFβ. The formation of the Runx1- CBFβ 
complex increases the binding affinity of Runx1 to DNA by two-fold (Bae SC, 1994). To 
evaluate whether transactivation of Runx1 can be improved by the presence of CBFβ, we 
performed the luciferase reporter assay with and without CBFβ along with Runx1-WT, 
5F and 5D. The exogenous CBFβ was expressed much higher than the endogenous CBFβ 
in HEK293T cells, but this abundance did not increase the Runx1 transactivity (Figure 
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4C). Surprisingly, transactivation of 5D decreased in the presence of CBFβ. On the other 
hand, protein levels of WT and 5F increased when co-expressed with CBFβ, supporting 
the conclusion that CBFβ stabilizes Runx1 and also indicating that basal CBFβ level is 
limiting compared to WT and 5F expression. 
 
3.2 Tyrosine phosphorylation of the C-terminal cluster activates 
myeloid-specific genes 
In order to study the effect of tyrosine phosphorylation of Runx1 in the myeloid 
setting, we generated 32Dcl3 progenitor cells that stably expressing the Runx1-WT-
ER(T) and its variants 4F-ER(T) and 4E-ER(T) in pBabePuro retroviral vectors. These 
cells contain both endogenous Runx1 and the ectopically expressed Runx1-ER. 
First, we demonstrated that tyrosine phosphorylation of Runx1 occurred in 
myeloid cells. The 32Dcl3 cells stably expressing the WT-ER(T) were cultured in growth 
media with the addition of either mIL3 or G-CSF cytokines, then pre-treated with PP2 
pan-tyrosine kinase inhibitor or in DMSO vehicle control for 24 hours before total 
protein lysates were harvested, which were then used for immunoprecipitation with ERα 
antibodies, followed by SDS-PAGE and Western Blot. The level of tyrosine 
phosphorylation in Runx1 was detected using anti-phospho-tyrosine antibodies. Tyrosine 
phosphorylation was observed in the 32Dcl3-pBabePuro-Runx1-ER(T) cells grown in 
both mIL3 and GCSF. After PP2 treatment, the phosphorylation level was reduced to 
approximately 50% relative to that without PP2 treatment, as confirmed by densitometry 
(Figure 5A). Therefore, this observation supports that tyrosine phosphorylation occurred 
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in 32Dcl3 myeloid progenitors and Src inhibition reduces WT-ER(T) phosphorylation 
grown in both mIL3 and G-CSF. 
We also compared the tyrosine phosphorylation level of Runx1-ER(T) to its 
phospho-null mutant 4F-ER(T) (Figure 5B). Two 32Dcl3 subclones expressing similar 
levels of WT-ER and 4F-ER(T) respectively were cultured in mIL3 cytokines and were 
treated with 4HT for 24 hours. Total protein lysates from these subclones were then 
immunoprecipitated with ERα antibodies followed by Western Blot to assess the 
expression for Runx1 and phopho-tyrosine. The phosphorylation levels of both subclones 
of 4F-ER(T) was 2-fold lower than that of WT-ER(T), indicating that the 4F-ER(T) was 
deficient in tyrosine phosphorylation. The reduced level of phosphorylation was further 
verified by densitometry. 
In the luciferase reporter assay in 293T cells, Runx1 displayed high 
transactivation activity when at least 2 tyrosine residues, Y375 and Y378 or Y379 and 
Y385 were phosphorylated. The optimal effect of Runx1 transactivation on myeloid cell 
– specific target genes was further evaluated in the WT-ER(T), 4F-ER(T) and 4E-ER(T) 
32Dcl3 pooled transductants. C/EBPα is essential to the differentiation of granulocytes 
and monocytes, whereas PU.1 is crucial to the formation of monocytes. We predicted that 
the tyrosine phosphorylation of Runx1 contributes to the downstream regulation and 
activation of Cebpα and PU.1. Total protein lysates were extracted form the pooled 
transductants and were analyzed for the expressions of Runx1-ER, C/EBPα or PU.1, with 
and without 4HT induction for 24 hours. On Western Blot, the expressions of Runx1-
WT-ER(T), 4F-ER(T) and 4E-ER(T) were relatively even and similar after 4HT 
induction. However, only WT-ER(T) and 4E-ER(T) caused an elevated expressions of 
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endogenous C/EBPα and PU.1(Figure 6A), as confirmed by densitometry. Our results 
clearly exhibited that expressions of Runx1-WT-ER(T) and to a lesser extent 4E-ER(T) 
increased protein production of endogenous C/EBPα and PU.1, while the 4F-ER(T) was 
ineffective  
The protein expression profiles of C/EBPα and PU.1 were verified with 
quantitative expression analysis of Cebpα and PU.1 mRNA, which is a more direct 
measurement of Cebpα and PU.1 gene activation or transcription. Total cellular RNAs 
were extracted from the same pooled transductants and were evaluated by quantitative 
RT-PCR. Similar to their protein expression, WT-ER(T) and 4E-ER(T) exhibited 2-fold 
higher mRNA expression of Cebpα and PU.1 relative to the Puro vector control but not 
with 4F-ER(T) (Figure 6B). This further confirmed that phosphorylation of the C-
terminal tyrosine clusters on Runx1 were important to trigger the activation of Cebpα and 
PU.1 transcription, resulting in higher mRNA levels and higher protein expressions. 
 
3.3 Loss of tyrosine phosphorylation of Runx1 reduces its DNA binding 
affinity 
The activation of Cebpa and PU.1 transcription could be a consequence tyrosine-
phosphorylated Runx1 binding to its consensus sequences at the regulatory promoter and 
enhancer regions of Cebpa and PU.1 respectively. The binding of Runx1 on Cebpa and 
PU.1 promoter had previously been reported (Guo 2012; Huang G, 2008). Therefore, we 
proceeded to examine the binding affinity between Runx1 and its mutant variants using 
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Electrophoretic Mobility Gel Shift (EMSA) and Chromatin-Immunoprecitation (ChIP) 
assays.  
HEK293T cells were transfected with CMV-Runx1, 5F, 5D, 4F or 4D. Nuclear 
extract and cytoplasm prepared from these transfected cells were resolved on 8% SDS-
PAGE to determine the exact compartmentalization of the Runx1 protein. Consistent with 
Runx1 characterization in earlier reports (Lu J, 1995; Kanno 1998), Runx1 protein was 
identified in the nuclear extract and not in the cytoplasm (Figure 7A). Lamin B is a 
protein specifically located in the nuclear compartment (Moir RD, 2000) while GAPDH 
was more abundant in cytoplasm (Mazzola JL, 2003), as shown in Figure 7A.    
Protein expression of 5D and 4D of the transfected HEK293T cells was 
consistently higher than Runx1 and the phospho-null F mutant variants. This 
phenomenon was also present when resolving the nuclear extract of transfected 
HEK293T cells, and therefore must be taken into account when running the mobility shift 
assay. In order to evaluate whether the higher protein expression of 4D was not due to the 
stabilizing effect of endogenous CBFβ in HEK293T cells, we co-transfected Runx1, 4F 
and 4D together with CBFβ, and then inspected the Runx1 protein expressions in the 
nuclear extracts. Presence of CBFβ did not increase the protein expression of 4D, but 
rather caused a slight reduction. Surprisingly, 4F showed a slightly higher protein 
expression in the nuclear extract (Figure 7B, right). The reason for this phenomena was 
unclear but it was further confirmed by the higher 4F and lower 4D total protein lysates 
in a separate Western Blot (Figure 7C). 
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The input amount of Runx1 nuclear extracts was adjusted accordingly for EMSA 
so that equal amounts of nuclear proteins from transfected HEK293T were utilized for 
binding to the radio-labeled Runx1 consensus oligonucleotides. The DNA-protein 
complex was then resolved, followed by exposure to autoradiography to detect the 
presence of DNA-protein complex of Runx1 or of its mutant variants. Of note, because 
Runx1-WT consistently expressed lower protein expressions compared to 5F and 4D, two 
concentrations of Runx1 protein were used; one that was identical to all the mutant 
variants used and one that was twice that concentration, as indicated by the italicized 
label in Figure 8A. Runx1 and its phospho-mimetic mutant variants, 5D and 4D bond 
more strongly to the consensus sequences. Conversely, 5F, 4F, 2F* and 2F displayed 
minimal binding (Figure 8A, left). As 5D and 4D always showed higher protein 
expressions, I also reduced the input amount for EMSA but this effort failed to generate 
DNA-binding. This might reflect the possibility of the simultaneous dilution of 
endogenous CBFβ or other cooperating factors in HEK293T cells when reducing the 
input nuclear protein of 5D or 4D, therefore ameliorating the occurrence of DNA binding 
(data not shown). 
 As discussed earlier, CBFβ increased DNA binding affinity of Runx1. Therefore, 
when provided with exogenous CBFβ, the overall binding affinity of Runx1-WT, 4F and 
4D to the consensus sequences was increased. However, 4F still showed weaker binding 
compared to Runx1 and 4D (Figure 8A, right). 
We were also concerned that the endogenous CBFβ would affect the binding of 
Runx1 in the EMSA assay. Therefore, EMSA was repeated using proteins generated in 
vitro with cellular components isolated from reticulocytes, provided in the IVT system 
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(In vitro transcription-translation, Promega). Again, in Western Blot, 5D demonstrated 
the highest protein expression, followed by Runx1-WT, then 5F, although equal volumes 
of translated proteins were analyzed (Figure 8B, top).  The doublets observed in 5F were 
not degradation products as verified by the addition of MG132 proteosomal inhibitor 
(Figure 8B, bottom). The volume of IVT products of WT, 5F and 5D was adjusted 
accordingly based on densitometry to equalize the total input amount for EMSA, either 
alone or with CBFβ. The absence of CBFβ impaired the ability of Runx1 to bind to its 
consensus sequence but the binding was rescued significantly when EMSA was carried 
out with CBFβ (Figure 8C).  However, the binding of 5F was again weaker compared to 
WT and 5D. Therefore, this result suggests that tyrosine phosphorylation of Runx1 
neither mimics the function of CBFβ nor relieves its dependence on CBFβ for optimal 
DNA binding. 
The differential DNA binding of Runx1 and its tyrosine mutant variants can be 
further validated using 32Dcl3 myeloid progenitor cells that stably expressing Runx1-
WT-ER(T), 4F-ER(T) and 4E-ER(T). The ability of the Runx1-WT, 4F or 4E to bind the 
enhancer regions of endogenous Cebpα and PU.1 was assessed with ChIP assay. After 
the DNA-protein complex was immunoprecipitated in the 32Dcl3 stable cell lines 
expressing these transgenes, quantitative PCR was performed to measure the abundance 
of the regulatory DNA. Runx1-WT bound strongly to the +37 kb Cebpα enhancer and the 
-14 kb PU.1 enhancer at 15-20 fold higher, which contained functional Runx1 binding 
sites but not at the actin promoter or the -2.5 kb region of Cebpα locus, which did not 
harbor any Runx1 binding consensus sequences (Figure 9A). 4E-ER(T) showed 15-20 
fold higher binding to Cebpα and PU.1 enhancers, similar to that of WT-ER(T). 4F-
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ER(T) displayed the opposite result, in which the binding was minimal (Figures 9B and 
9C). Consistent with the EMSA data, Runx1-WT and 4E manifested significant increased 
binding affinity for the 2 enhancers that contain functional Runx1 binding sites. This 
result also reinforces our observations of Cebpα and PU.1 mRNA and protein 
expressions in Figures 6A and 6B, in which tyrosine phosphorylation of Runx1 played a 
crucial role in triggering the expression of C/EBPα and PU.1, partly through its DNA 
binding to Cebpα and PU.1 enhancers.  
 
3.4 Tyrosine phosphorylation stabilizes Runx1 and protects it from 
ubiquitin-mediated degradation 
Phospho-mimetic Runx1 – 5D and 4D showed a higher expression in Western 
Blot compared to 5F and 4D (Figure 3A). In addition, Runx1 protein expression was also 
elevated in the presence of Src (Figure 4A). These two observations suggested that 
tyrosine phosphorylation might contribute to the stability of the Runx1 protein and thus 
prompted us to further inspect the half-life of these protein products with the help of 
cycloheximide. Cycloheximide (CHX) blocks protein synthesis by interfering with its 
elongation step (Schneider-Poetsch, 2010). Therefore, the amount of protein that would 
be detected after treating the cells with CHX would reflect the rate of degradation or 
accumulation of that particular protein.  
We expressed Runx1-WT alone or with Src(E381G) in HEK293T cells, treated 
the transfected cells with cycloheximide at specific time-points, and then monitored the 
Runx1 protein expressions over 8 hours (Figure 10). Runx1-WT protein expression by 
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itself was moderate at time 0 and began to showed reduction between hour 4 and hour 6 
after CHX addition. On the contrary, Runx1-WT expression was markedly increased at 
time 0 in the presence of Src(E381G), and this elevated expression maintained through 
the 8 hours of analysis. This result supported our observations in Figure 4A that Src could 
dramatically increase and stabilize the Runx1 expression. Furthermore, it also suggests 
that a large amount of exogenous Runx1 protein was not tyrosine phosphorylated due to 
the limiting level of endogenous Runx1 in HEK293T cells. 
Protein expressions of 5D, 5F, 4D and 4F were also examined with CHX. 5D and 
4D showed identical protein expression profiles as that of WT + Src(E381G). Beginning 
from time 0, 5D and 4D were expressed relatively higher than WT, and this level was 
constant for 8 hours after CHX treatment. In contrast, while 5F and 4F protein 
expressions were higher than WT, the expression levels started to diminish earlier than 
WT, which was between hour 2 and hour 4 post-CHX treatment (Figure 10). These 
results indicate that tyrosine phosphorylation contributes to the stability of Runx1 
proteins and therefore may affect the higher transactivation potential of Runx1. 
CBFβ protein was known to protect Runx1 from ubiquitination-mediated 
degradation and therefore stabilizes Runx1 (Huang G, 2001). We also co-transfected 
CBFβ together with WT, 5F and 5D in HEK293T cells and compared their Runx1 protein 
expressions (Figure 10). Similar to the effect of Src(E381G), Runx1 protein expressions 
of WT, 5F and 5D were higher than that of WT alone, and these elevated expressions 
were maintained throughout the 8 hours in the presence of CBFβ. This observation was 
not surprising given that CBFβ was known to increase the stability of Runx1 transcription 
factor (Huang G, 2001).  
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However, it might be possible that the binding kinetics between Runx1 and CBFβ 
would be altered in response to tyrosine phosphorylation. To further investigate the 
association of CBFβ to Runx1-WT, 5F or 5D, we took advantage of the availability of 
pEF1α vectors expressing FLAGBio-Runx1-WT, 5F or 5D. The incorporation of biotin 
molecules onto the Runx1 proteins enables protein pulled-down using streptavidin 
agarose. This method has been established and widely used for affinity purifications 
(Kim J, 2009). Another reason to choose streptavidin pull-down instead of Runx1 
immunoprecipitation was due to the concern that Runx1 antibodies might interfere with 
Runx1- CBFβ interactions.  When equal input amounts of FLAGBio-Runx1-WT, 5F or 
5D total protein lysates were pull-down with strepavadin agarose, we noticed that CBFβ 
bonded at similar strength to each of these protein products (Figure 11B). Hence, the 
increased stability of non-phophorylated Runx1 in the presence of CBFβ was 
independent of the physical binding interaction between CBFβ and Runx1. 
 Protein stability is related to its rate of degradation at physiological condition. 
There are several molecular mechanisms that facilitate protein degradation, and one of 
them is ubiquitinylation-mediated proteosomal pathway (UPP). To detect the differential 
interaction of Runx1 and its mutant variants to ubiquitination, I co-transfected the 
HEK293T cells with WT, 5F and 5D along with HA-tagged ubiquitin, and carried out co-
immunoprecipitation using Runx1 antibodies and with an equal input amount of total cell 
lysate (Figure 11A). 5F displayed the strongest association with HA-tagged ubiquitin, 
suggesting that 5F was a better target substrate for ubiquitins. In contrast, WT showed 
only moderate binding to HA-tagged ubiquitin, while 5D displayed minimal binding to 
HA-tagged ubiquitin (Figure 11A, right). In an attempt to detect binding of ubiquitin to 
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5D, we increased the loading volume to 6X higher, and obtained the autoradiograph at 
3X longer exposure time. In spite of this, the co-immunoprecipitated HA-tagged 
ubiquitin bands were still barely visible (Figure 11A, right). It should be noted that the 
molecular weight of Runx1 protein is 55 kDa, which is similar to that of immunoglobulin 
heavy chain (IgH). Therefore the Runx1 bands were masked by the intense IgH bands on 
Western Blot. 
Ubiquitins are transferred to the target proteins through the catalytic action of 
Ubiquitin Ligases. Anaphase Protein Complex (APC) is a major Ubiquitin Ligase III in 
the UPP degradation system, in which its catalytic functions are assisted by two adaptor 
proteins, Cdc20 and Cdh1. One early report demonstrated that Cdc20 promotes the 
degradation of phosphorylated Runx1 at Serine-303, whereas Cdh1 targets for total 
Runx1. (Biggs JR, 2006).  
Finally, to determine the ability of Cdc20 or Cdh1 to mediate Runx1 degradation, 
we compared the protein expressions of Runx1-WT, 5F and 5D after co-transfecting 
them with either Cdc20 or Cdh1. Runx1-WT was resistant to Cdc20 but was gradually 
degraded in the presence of Cdh1 in a dose-dependent manner (Figure 12A). Reduction 
of Runx1-WT protein expression was already visible with 1 μg of Cdh1 compared to 
without Cdh1, and its expression dropped to 5-fold lower in 5 μg of Cdh1, as assessed 
with densitometry. Similar to WT, 5F and 5D did not respond to 1 μg or 5 μg of Cdc20. 
Furthermore, 5D appeared to become about 3 times more stable in both amounts of 
Cdc20 and the reason for this phenomenon is unclear. Protein expression of 5F was 2/3 
lower at 1 μg or was 1/3 lower at 5 μg of Cdh1. Reduction of 5D protein expression was 
only observed in 5 μg of Cdh1, which was 2/3 lower compared to without Cdh1 (Figure 
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12B). The observations of WT, 5F and 5D in Cdh1 suggest that the non-phosphorylated 
form of Runx1 is the preferred substrate of Cdh1 in the UPP system. It also raises the 
possibility that the markedly increased stability of 5D is partially due to protection from 
Cdc20 or Cdh1-mediated degradation. Further evaluations are needed to elucidate the 
underlying molecular mechanisms, the structural interactions between Runx1 and Cdh1, 
and the consequences of these interactions. 
 
3.5 Exogenous Src activates Runx1 and C/EBPα expression in SHP2-
knock down 32Dcl3 myeloid progenitors 
 As we gathered more evidences supporting the role of Runx1 tyrosine 
phosphorylation in C/EBPα induction, we wanted to further examine whether SHP2 
tyrosine phosphatase has an effect on Runx1 and C/EBPα productions. A recent 
publication showed that blocking of SHP2 activity in 32Dcl3 myeloid progenitor cells 
suppressed its endogenous expression of C/EBPα in response to G-CSF (Zhang L, 2011). 
The 32Dcl3 myeloid progenitor cells established in this report, that stably expressing 
RNA interference of SHP2 (77-10) were utilized in this investigation. A second retroviral 
vector, pBabeNeo carrying the cDNA of Src(E381G) upstream of ER(T) element was 
transduced into 32Dcl3-77-10. The pooled double transductants were cultured for 24 
hours, and for another 24 hours with 4HT addition. Equal amounts of the total protein 
lysates were used to detect the protein expression of Runx1 and C/EBPα. In both 32Dcl3-
77-10, with and without the pBabePuro retroviral vector, Runx1 expression level was 
moderate. Moderate elevation of Runx1 expression could be observed after Src was 
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introduced compared to the pBabeNeo control (approximately 1.3-fold), implying that 
Src was acting downstream in epistasis of SHP2. Consistent with the effect of 
cooperative interaction between Src and Runx1, the diminished expression of C/EBPα in 
32Dcl3-77-10 was at least partly rescued in the presence of exogenous Src, in which its 
protein expression was about 2.2-fold higher (Figure 13). This result lends additional 
support to the idea that SHP2 mediates Src to activate Runx1 and that Runx1 activates 






















Figure 2: Schematic diagrams of murine Runx1b and Runx1 luciferase reporter construct. 
A. Diagram describing the locations of DNA-binding runt domain (DBD), transactivation 
domain (TAD) and repression domain (REP), with sites of tyrosine modifications 
mapped. The 5 tyrosine residues modified in this study are indicated (top), and the 
combinations of altered tyrosine residues in Runx1 mutant variants are listed (below). B. 
Runx1 luciferase reporter gene construct consists of 4 binding sites of Runx1 at the 5’-
terminal [(CBF)4] and the luciferase reporter gene at the 3’-terminal (Luc) preceded by 
the minimal thymidine kinase promoter (TK). Runx1 protein binds to the (CBF)4 region 
thus activating the transcription of luciferase gene via TK promoter. SRC interacts with 
Runx1 to affect differential transcription levels of luciferase enzymes. Interaction of Src 




Figure 3: Transactivation and expression of Runx1 and its tyrosine mutant variants. A. 
1×105 HEK293T cells plated on a 24 well plate were transiently co-transfected with 150 
ng of (CBF)4-TK-Luc, 0.8 ng of CMV-β-Gal and 5 ng of CMV vectors expressing wild-
type Runx1 (WT) or its respective tyrosine mutant variants or vector only. The luciferase 
and beta-galactosidase activity was measured after 48 hours. Fold activation was 
expressed as the ratio of luciferase and beta-galactosidase activity after normalizing to that 
of CMV vector alone controls, which was set to value 1. Mean and SE were obtained from 
three determinations. *-p<0.05, **-p<0.01, ***-p<0.001(top). 4×105 HEK293T cells 
plated on a 6 well plate were transfected by 1 μg of CMV vectors expressing wild-type 
Runx1 (WT) or its respective tyrosine mutant variants or vector only. Equal quantities of 
total protein lysates were separated on 8% SDS-PAGE after 48 hours, followed by the 
assessment of Runx1 and β-actin expressions by Western Blot (bottom). B. Luciferase 
reporter assay (top) and protein expression analysis (bottom) was repeated as described in 
A, using CMV vectors expressing WT or its respective tyrosine mutants (left) or pEF1α 




Figure 4: Transactivation and expression of Runx1 and its tyrosine mutant variants in the 
presence of protein tyrosine kinases and CBFβ. For all fold-activation shown for 
luciferase reporter assay, mean and SE were obtained from 3 determinations. A. 
Luciferase reporter assay (top) and protein expression analysis (bottom) were performed 
as described in Figure 2, with or without 40 ng of pCEFL-Src(E381G). The fold effects of 
Src expression on the average activity of CMV vector, -WT or -5F alone are also 
indicated. B. Luciferase reporter assay was carried out as described in A, using 40 ng of 
pCEFL-Src(E381G), Fes or MIG-Jak(V614F). Fold changes between CMV-WT without 
versus with protein tyrosine kinase are indicated. C. Luciferase reporter assay (top) was 
repeated as described in A, with or without 1 μg of CMV-CBFβ. Relative fold activations 
are shown. Equal quantities of total protein lysates were separated on 8% SDS-PAGE 
after 48 hours, followed by the assessment of Runx1, β-actin and CBFβ expressions by 










Figure 5: Tyrosine phosphorylation of exogenous Runx1. A. Equal numbers of 32Dcl3 
cells stably expressing WT-ER(T) were grown in either mIL3 or 24 hours after transfer to 
G-CSF cytokine, with and without addition of 20 μM PP2 or DMSO control for 8 hours. 
Total protein lysate was subjected to ERα immunoprecipitation, followed by 10% SDS-
PAGE and Western Blot to assess tyrosine phosphorylation levels. The ratios of 
phosphorylated to total WT-ER(T) are shown. B. Equal quantities of total protein lysates 
extracted from 2 subclones each of 32Dcl3 stable cells expressing WT-ER(T) and 4F-
ER(T) were subjected to mouse ERα immunoprecipitation. The immunoprecipitant was 
resolved in 10% SDS-PAGE and was transferred to PVDF membrane followed by 
immunoblotting using phospho-tyrosine and ERα antibodies. The ratios of phosphorylated 










Figure 6: Protein and mRNA expression of Runx1 molecular targets. A. Equal quantities 
of total protein lysates equivalent to 2×105 of 32Dcl3 cells that stably expressed 
pBabePuro vector, Runx1-WT-ER(T), 4F-ER(T) or 4E-ER(T) cultured in the absence or 
presence of 4-hydroxytamoxifen (4HT) for 24 hours were separated in 8% SDS-PAGE 
and were subjected to Western Blot using ERα, C/EBPα, PU.1 or β-actin antibodies. Fold-
increase induced by 4HT, normalized to β-actin is measured by densitometry. B. Total 
RNA from the same cell cultures as described in A were subjected to mRNA expression 
analysis. After reverse-transcription, 5 ng of cDNA was used for quantitative PCR to 
assess the expression level of Cebpa and PU.1, with Actin as internal control. The relative 
expressions of Cebpa or PU.1 before and after 4HT induction were normalized to 
pBabePuro vector, in which the value is set to 1. Mean and SE were obtained from three 








Figure 7: Localization and expression of Runx1 in nuclear compartment. A. 3×106 
HEK293T cells plated on a 10 cm culture dish were transiently co-transfected with 6 μg of 
CMV vectors expressing wild-type Runx1 (WT) or its respective tyrosine mutant variants 
or vector only. Nuclear and cytoplasmic extracts from equal cell numbers were harvested 
after 48 hours and were resolved in 8% SDS-PAGE, followed by immunoblotting using 
Runx1, Lamin B, GAPDH or b-actin antibodies. B. Similar transient transfection was 
repeated as described in A, using 6 μg each of CMV vectors expressing Runx1-WT, 5F, 
4F, 2F*, 2F, 5D, 4D or 3 μg of each of WT, 4F, 4D with or without 3 μg of CMV-CBFβ. 
Runx1 protein level is assessed from the nuclear extract prepared 48 hours later using 
Western Blot. C. 4×105 HEK293T cells plated on a 6 well culture dish were transiently 
co-transfected with 1 μg of CMV vectors expressing 4F or 4D with or without 3 μg of 
CMV-CBFβ. Total protein lysates were harvested after 48 hours, and subjected to 







Figure 8: Tyrosine phosphorylation of Runx1 mediates DNA binding. A. 6 μg of nuclear 
extracts, individually prepared from transiently transfected HEK293T cells as described in 
Figure 6B, were subjected to electrophoretic mobility gel shift analysis (EMSA). Prior to 
EMSA, the nuclear extracts were mixed with a radio-labeled double-stranded DNA 
containing a Runx1 binding consensus sequence found at the myeloperoxidase promoter. 
Lanes with 12 μg of WT or WT with CBFβ were included, labeled as WT. “*” marks the 
location of the specific gel shift band. E. In vitro transcription-translational (IVT) products 
were generated from 1 μg of linearized CMV vectors expressing Runx1-WT, 5F, 5D or 
CMV vector expressing CBFβ. Equal volumes of IVT products including the negative 
control with reticulocyte lysate alone were then separated in 8% SDS-PAGE and were 
subjected to Western Blot to access the expression of Runx1 and CBFβ (top). Similarly, 
IVT products of 5F with and without treatment of 25 μM MG132 protease inhibitor were 
analyzed (bottom). C. After equalizing IVT products of WT, 5F or 5D using densitometry, 








                 
 
 
Figure 9: Tyrosine phosphorylation of Runx1 promotes binding to endogenous promoters 
and enhancers assessed with Chromatin Immunoprecipitation (ChIP). A. 1×106 32Dcl3 
cells stably expressing Runx1-WT-ER(T), 4F-ER(T), 4E-ER(T) or vector only (Puro) 
were cultured for 24 hours after addition of 4HT, and were subjected to ChIP assay using 
2 mg of IgG (Ig) or rabbit anti-ERa (ER) antibodies, followed by quantitative PCR using 
primer pairs targeted to +37 kb Cebpa enhancer, -14 kb PU.1 enhancer, -2.5 kb Cebpa 
promoter, or β-actin promoter. The relative binding of ER to each of these DNA elements 
in WT-ER(T) compared to that of Ig is shown. Mean and SE were obtained from three 
determinations. ChIP was performed as described in A to evaluate the relative binding of 
+37 kb Cebpa enhancer (B) or -14 kb PU.1 enhancer (C) between WT-ER(T), 4F-ER(T), 











Figure 10: Src or tyrosine phosphorylation of 
Runx1 enhances the stability of Runx1 
protein. 4×105 HEK293T cells plated on a 6 
well culture dish were either transiently 
transfected with 1 μg of CMV vectors 
individually expressing WT, 5F, 5D, 4F or 
4D, or co-transfected with 0.25 μg of CMV-
WT + 1 μg pCEFL-Src or 1 μg of CMV-WT, 
5F, 5D + 1 μg CMV-CBFβ for 48 hours. 
Cycloheximide was added into the 
transfected cells 0.5 – 8 hours before total 
protein lysates were prepared from equal 
number of cells. The expressions of Runx1 
isoforms were assessed by 8% SDS-PAGE 
and immunoblotting with Runx1 antibodies 
or β-actin as a loading control. Data 
presented here were the representative of 




Figure 11: Tyrosine phosphorylation protects Runx1 from ubiquitinylation but does not 
affect the binding affinity to CBFβ. A. 4×105 HEK293T cells plated on a 10cm culture 
dish were transiently co-transfected with either 2 μg of CMV-WT, 1 μg of  -5F, or 0.4 μg 
of -5D + 3 μg of pCMV-HA-ubiquitin (HA-Ub). Total protein lysates prepared from these 
transfected cells 48 hours later were subjected to Western Blot (left) and were also 
immunoprecipitated with IgG (Ig) or mouse-anti-HA antibodies (HA) (middle and right). 
Amount of protein lysate loaded for 5D was adjusted to 1/12  (left and middle) or 1/2 
(right) that of WT and 5F. B. 4×105 HEK293T cells plated on a 10cm culture dish were 
transiently co-transfected with 1.5 μg of CMV-CBFβ + 1.5 μg of pEF1α-birA + 3 μg of 
pEF1α-FLAGBio-WT, 5F or 5D. Total protein lysates were harvested after 48 hours, and 
equal amount of protein lysates were subjected to immunoprecipitation using streptavidin 
agarose, followed by 12% SDS-PAGE and Western Blotting with Runx1 and CBFβ 




                       
 
Figure 12: Non-tyrosine phosphorylated Runx1 is a specific substrate of Cdh1, the adaptor 
protein of APC ubiquitin ligase III, in a dose-dependent manner. A. 4×105 HEK293T cells 
plated on a 6 well culture dish were transiently co-transfected with 2 μg of CMV-WT and 
1 to 5 μg of pCMV-HA-Cdc20 or Cdh1 expression vectors. Equal amounts of total protein 
lysates were resolved in 8% SDS-PAGE followed by the assessment of Runx1, HA and β-
actin expressions by Western Blot. The relative intensities of the Runx1 bands after 
normalizing to β-actin bands are shown below each lane. Data shown is the representative 
experiment from 4 replicates. B. Similar transient co-transfections were carried out as 
described in A using 1 μg of CMV-5F or 0.5 μg of CMV-5D and 1 or 5 μg of pCMV-HA-
Cdc20 or Cdh1 expression vectors, followed by analysis of Runx1, HA and β-actin 
expressions using Western Blot. The relative intensities of the Runx1 bands after 
normalizing to β-actin bands are shown below each lane. 
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Figure 13: Exogenous Src induced Runx1 and C/EBPα expressions in SHP2 deficient 
32Dcl3 myeloid progenitor.  32Dcl3 cells harboring a pBabePuro retroviral vector that 
constitutively repressing the SHP2 mRNA expression were transduced again with 
pBabeNeo retroviral vector, or pBabeNeo carrying the cDNA of Src-ER(T). Equal 
quantities of total protein lysates equivalent to 2×105 of 32Dcl3 stable double 
transductants cultured in the presence of 4-hydroxytamoxifen (4HT) for 24 hours were 
separated in 8% SDS-PAGE and were subjected to Western Blot using Runx1, C/EBPα, 
or β-actin antibodies.   
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CHAPTER 4: DISCUSSION AND CONCLUSION 
In this study, we have demonstrated that tyrosine phosphorylation of Runx1 at 
residues Y260, Y375, Y378, Y379 and Y386 by Src or potentially other tyrosine kinases 
increases its transactivation potency and DNA binding ability to its consensus sequences, 
resulting in the induction of the C/ebpα and PU.1 mRNA and protein expression. The 
study also showed that tyrosine phosphorylated Runx1 is more stable due to its longer 
half-life, binds less to ubiquitin and is protected from the Cdh1-mediated ubiquitin 
proteosomal pathway. 
Tyrosine phosphorylation of Runx1 has only been recently reported in 
megakaryocytes and thymocytes (Huang H, 2012). However, Runx1 transactivation upon 
tyrosine phosphorylation in these and all other blood lineages remained to be investigated. 
Src phosphorylates Runx1 at Y260, and four tyrosine residues at the C-terminal, Y375, 
Y378, Y379, and Y386. In the luciferase reporter assay on HEK293T cells, we 
demonstrated that Src strongly synergized with Runx1 to increase its transactivation. 
Mutation of the five tyrosine residues to phenylalanine (Runx1-5F) to block 
phosphorylation obviated Runx1 transactivity. Interestingly, mutations of the C-terminal 
cluster (Runx1-4F, 2F or 2F*) to phenylalanine were sufficient to abolish Runx1 
transactivity but not the mutation of individual tyrosine to phenylalanine. This 
observation shows that either Y375/Y378 or Y379/Y386 could significantly affect the 
transactivation potency of Runx1. It has been shown that a combinatorial phosphorylation 
effect from multiple tyrosines on G-CSF receptor contributes to proliferation, 
differentiation and survival signals in 32Dcl3 myeloid progenitors (Ward AC, 1999). 
Combination of different multiple phosphorylation sites on Runx1 led to different levels 
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of hematopoietic development (Yoshimi M, 2012). Therefore, mapping the exact 
combination of tyrosine residues modified by Src to influence Runx1 transactivity could 
be important step to elucidate the signaling pathways in myeloid progenitors. 
In addition to Src, several other tyrosine kinases are activated in G-CSF signaling, 
contributing to the maturation of myeloid progenitors (Miranda MB, 2007). Although we 
found that the level of tyrosine phosphorylation of the exogenous Runx1-ER expressed in 
32Dcl3 cells was significantly reduced upon treatment with PP2, a non-selective Src 
kinase inhibitor, we could not be certain that Src was the most relevant tyrosine kinase to 
regulate the optimal Runx1 transactivation. Therefore, we further evaluated the ability of 
two other tyrosine kinases, Fes and Jak2 that are abundantly expressed in myeloid 
lineages, to affect Runx1 transactivation. We showed that both activated Fes and 
activated Jak2 failed to increase the transactivity of Runx1 in the luciferase reporter assay, 
implying that Runx1 is not their substrate of choice. This observation was unexpected, as 
Fes and Jak2 are expressed during myeloid differentiation and their activation upregulate 
Runx1 targets, C/EBPα and PU.1 (Kim J, 2004; Irino T, 2011). It is possible that Fes and 
Jak2 may mediate other functions of Runx1 aside from transactivity in granulopoiesis, as 
precedent studies have reported that members of the Src family kinases could affect both 
proliferation and differentiation of myeloid progenitors (Mermel CH, 2006). In the future, 
we could expand our investigation to other hematopoietic cell-specific tyrosine kinases 
that may display overlapping functions with Src. For example, Jak3 expression increased 
during granulopoiesis in 32Dcl3 cells, and Hck is highly expressed in granulocytes (Rane 
SG, 2002; English BK, 1996), and therefore may regulate Runx1 transactivity.   
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In order to discover the biological effects of phosphorylated Runx1 in a myeloid 
setting, 32Dcl3 mouse progenitor cell line were used as the study model. 32Dcl3 are 
bipotential, non-tumorigenic myeloid progenitor cells derived from the murine bone 
marrow, and are strictly interleukin-3 (IL3) dependent for cell proliferation and survival 
(Valtieri M, 1987). Replacement of G-CSF into the growth media triggers its terminal 
differentiation into functionally mature granulocytes (Guchhait P, 2003).   
The exogenous Runx1 (WT-ER) and its phospho-mimetic C-terminal tyrosine 
mutant (4E-ER) induced the transcription of endogenous Cebpα and PU.1 and their 
protein production in 32Dcl3 myeloid cells. Mutation to phenylalanine (4F-ER) obviated 
this effect. Diminished C/EBPα transcription, resulting in inhibition of myeloid 
differentiation, may contribute to leukemic transformation in AML cases associated with 
decreased RUNX1 activity (Guo H, 2012). To provide further support on the effect of 
phosphorylation that is controlled by Src and SHP2, protein expressions of endogenous 
Runx1 and C/EBPα were down-regulated in SHP2 knock-down 32Dcl3 cells but was 
partially rescued after induction of exogenous Src. This observation is consistent with the 
previous report by Zhang et al., in which the authors demonstrated that exogenous Runx1 
(WT-ER) could moderately restored the diminished C/EBPα expression in the SHP2 
knock-down 32Dcl3 cells (Zhang L, 2011). Therefore, reduced tyrosine phosphorylation 
in Runx1, either due to diminished Src function, enhanced SHP2 activity or loss of 
tyrosine residues on Runx1, could potentially reduce Runx1 activity, thereby leading to 
down-regulation of C/EBPα, blocking granulopoiesis and contributing to myeloid 
transformation.   
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Of note, three phopho-mimetic mutants, 4E, 2E, and 2E* were generated by 
replacing tyrosine (Y) residues with glutamate (E) residues rather than aspartate (D) 
residues. Glutamate has an extra methyl group and thus could be a better representative 
of a bulky tyrosine residue.  
Hong et al. demonstrated that endogenous Runx1 binds to consensus sites at the 
Cebpa promoter and the +37kb enhancer region (Guo H, 2012). We further determined 
that the exogenous Runx1-4E-ER as well as WT-ER also bound to endogenous Cebpa 
enhancer in 32Dcl3 progenitor cells, but not 4F-ER. This was the first demonstration that 
tyrosine phosphorylation of Runx1 is required to mediate the physical interaction of 
Runx1 protein to the Cebpa and Pu.1 enhancers.  
We have also demonstrated that, in general, Runx1-4D and -5D bound strongly to 
the consensus sequences as assessed with EMSA. Conversely, Runx1-4F and 5F 
exhibited reduced DNA binding, which also reflected the loss of binding of Runx1 to 
enhancers of endogenous Cebpa and Pu.1 in the absence of tyrosine phosphorylation. 
Whether Runx1 tyrosine phosphorylation facilitates its binding to enhancers of other 
target genes remains to be determined. 
Runx1-5D and 4D phospho-null tyrosine mutants repeatedly displayed higher 
protein expressions compared to WT, 5F and 4F. Upon treatment with cycloheximide, 
elevated protein expression of Runx1-5D and 4D could sustain for 8 hours. This 
observation was consistent with the earlier report by Huang H et al., and provided 
additional support that tyrosine phosphorylation enhances Runx1 stability (Neel BG, 
2012; Huang H, 2012).  
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Apart from displaying a longer half-life, Runx1-5D also showed weak binding to 
ubiquitin and was resistant to Cdh1-mediated degradation compared with Runx1-WT. 
Conversely, Runx1-5F showed a shorter half-life in cycloheximide, bound strongly to 
ubiquitin, and was sensitive to Cdh1-mediated degradation. Interestingly, Cdc20 did not 
mediate the degradation of Runx1-WT and -5F, and could even stabilized Runx1-5D.  
Both Cdh1 and Cdc20 adaptor proteins are responsible for the substrate recognition and 
activating mechanism for anaphase-promoting complex (APC), and they can interact with 
specific substrates either independent of or dependent on APC (Pfleger CM, 2001). 
Zhang’s group demonstrated that Cdc20 preferentially targeted phosphorylated Runx1 
whereas Cdh1 could promote the degradation of total Runx1, which consists of both 
phosphorylated and non-phosphorylated Runx1 (Biggs JR, 2006). Our results showed the 
opposite; only Runx1-5F was targeted by Cdh1 for degradation, and all forms of Runx1 
was protected from Cdc20-mediated degradation. Hence, the differential interactions of 
tyrosine phosphorylated Runx1 with Cdh1 and Cdc20 could potentially reflect their 
substrate preferences.  
Transactivation of transcription factor is closely correlated with proteosomal 
degradation. Transcription factor with higher transactivity is degraded by proteasome at a 
faster rate (Molinari E, 1999). Our observation, again, contradicts this previous report. 
Runx1-5D showed the highest transactivity, but it was resistant to Cdh1 and Cdc20-
mediated proteosomal degradation. In order to further characterize the effect of Cdh1 on 
Runx1-WT, -5F and -5D, the physical association and the binding motifs of Cdh1 on 
Runx1 need to be identified. In addition, determining whether Cdh1 also mediates 
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degradation of Runx1-4F ad -4D will elucidate the relationship between tyrosine 
phosphorylation, transcriptional activity, and proteosomal degradation. 
Luciferase reporter assay, EMSA, and cycloheximide assay were repeated with 
the addition of exogenous CBFβ, which was produced either through co-transfection in 
293T cells or generated separately using IVT. As discussed in Chapter 1, CBFβ increases 
the DNA binding affinity and stability of Runx1 (Gu T-L, 2000). We observed a marked 
increased DNA binding of Runx1, and its tyrosine mutants to consensus sequence in the 
presence of CBFβ, and both Runx1-WT and -5F protein expression were stabilized across 
8 hours after cycloheximide treatment. However, the reduced transactivation of Runx1-
5F was not rescued by the addition of CBFβ. Furthermore, the binding affinity of Runx1-
WT, -5F and -5D to CBFβ was at similar levels as assessed by co-immunoprecipitation 
assay. These results indicated that phosphorylation at Runx1 C-terminal tyrosine cluster 
did not modify its binding interaction with CBFβ nor limit the access of CBFβ to its Runt 
DBD, although their association markedly increased the DNA binding affinity. In 
addition, Runx1-5D, alone, displayed minimal DNA binding in EMSA, implying that 
Runx1 tyrosine phosphorylation was insufficient to mimic or replace the function of 
CBFβ. It is possible that the allosteric changes at the Runx1 C-terminal after tyrosine 
phosphorylation do not affect Runx1-CBFβ heterodimerization. 
Runx1 molecule can serve as a scaffolding bridge to many co-regulators. Multiple 
cellular molecules form multimeric complexes with the different domains on Runx1 to 
modulate cell-specific gene expressions after exposure to extracellular stimuli. C-terminal 
domain of Runx1 is important in the interaction with the N-terminal of p300 to increase 
DNA binding (Yamaguchi Y, 2004). Their association along with CREB binding protein 
 
 59 
(CBP) contributed to the induction of granulocyte differentiation in response to G-CSF 
signaling (Kitabayashi I, 1998). Endogenous HDAC1 and HDAC3 were also shown to 
bind to C-terminal of endogenous Runx1 to markedly reduce its transactivity, and this 
interaction was impaired after Cdk-mediated S424 phosphorylation (Hong G, 2011).  
RUNX1-RUNX1T1 recruits HDACs to repress gene expressions for granulocyte 
differentiation (Hayashi Y, 2000, Gelmetti V, 1998). Therefore, it had been proposed that 
HDAC inhibitors or other epigenetic therapeutic approaches could be beneficial to 
reverse the granulocytic differentiation block caused by Runx1 mutation (Gozzini A, 
2003; Klisovic MI, 2003). 
Tyrosine phosphorylation of Runx1 is also one of the tightly orchestrated PTM 
that affect interactions between Runx1 and various molecular partners, and can further 
cross-talk with other PTM in the same protein to fine-tune signaling pathways (Hunter T, 
2014). Tyrosine modifications on Runx1 can reduce its interactions with transcriptional 
co-repressors to complement its ability to activate its transactivation potential (Lam K, 
2012). Based on the above observations, we could predict that the mutation of the C-
terminal tyrosine cluster (Y375, Y378, Y379 and Y386) to phenylalanine or to aspartate 
may influence the recruitment of HATs and HDACs. The identification of physical 
associations between HDACS and Runx1 tyrosine mutants was not included here, but 
Guo H continued the effort beyond this study, and the observation was reported recently 
(Leong WY, 2016). We demonstrated that mutation of C-terminal tyrosine cluster to 
aspartate greatly reduced its association to HDAC1 and HDAC3, and the mutation to 
phenylalanine reversed this effect. Consistent with the finding of Hong et al., this result 
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highlighted the functional importance of C-terminal domain of Runx1 in terms of 
interaction with epigenetic factors. 
Full length Runx1 exhibits auto-inhibition, partly due to its 3-dimensional 
conformation determined by circular dichroism spectroscopy. (Tang Y-Y, 2000). C-
terminal Runt DNA binding domain has also been shown to inhibit DNA binding or 
heterodimerization of CBFβ (Gu T-L, 2000).  Therefore, it is possible that tyrosine 
phosphorylation or other PTM of the Runx1 C-terminal domain is necessary to relieve 
inhibitory effects of its transcriptional activity. Besides HATs and HDAC binding, Runx1 
interacted with PMRT1/4/6, mSin3A, SUV39H1, CHIP and many other co-regulators 
(Chuang LSH, 2013; Shang Y, 2009). Therefore, it will be important in future studies to 
investigate the effect of Runx1 tyrosine modifications on the interaction with HATs and 
these additional co-activators and co-repressors.  
Tyrosine phosphorylation represents one of many PTM occurring in Runx1, but 
its biological effects on myeloid cell differentiation are significant (Neel BG; 2012). 
Given that tyrosine phosphorylated Runx1 showed higher transactivation, increased DNA 
binding affinity, and could induce endogenous C/EBPα and PU.1 expressions in 32Dcl3 
myeloid progenitors, we might predict that Runx1-5D would promote granulocyte 
differentiation. However, Cantor’s group described that exogenous Runx1-5D inhibits the 
development of CD8+ T cells in Runx1-deleted marrow cells and blocked the maturation 
of megakaryocytes in the erythroid cell line.  During megakaryopoiesis, Runx1 
suppressed KLF1 promoter to inhibit erythropoiesis (Kuvardina ON, 2015). Hence, it 
may be possible that Runx1-5D transactivation can simultaneously silence the genes 
required for thymocyte development and megakaryopoiesis while activating gene 
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expressions specific for maturation of granulocytes or other blood lineages. The effect of 
tyrosine phosphorylated Runx1 could be lineage dependent. Therefore, it is important to 
determine the effect of Runx1 tyrosine phosphorylation in granulopoiesis. Of note, this 
study was conducted by Guo H, in which exogenous Runx1-4E rescued the granulocyte 
formation in the lineage-negative bone marrow cells obtained from Runx1-deficient mice 
(Leong WY, 2016).  
Combining all these observations, we conclude that Src phosphorylation of Runx1 
at tyrosine residues increases its transactivity potency and DNA binding ability 
independent of its cofactor CBFβ, improves its stability by abolishing ubiquitination-
mediated proteosomal degradation, thereby inducing Cebpα and PU.1 mRNA and protein 
expression, which are the biological events that promote granulocyte differentiation. The 
findings that tyrosine phosphorylation of Runx1 by Src precedes the induction of C/EBPα 
also provide strong evidences to our proposed model of G-CSF signaling pathway 
(Figure 1), in which Src mediates the activation of Runx1 and that Runx1 activates 











4HT  4-hydroxytamoxifen 
AML  Acute myeloid leukemia 
APC  Anaphase promoting complex 
CBF  CREB binding protein 
CBFβ  Core binding factor β 
CBFβ-SMMHC Core binding factor β-smooth muscle myosin heavy chain 
Cdc20  Cell division cycle 20 
Cdk  Cyclin-dependent kinase 
C/EBPα CCAAT/enhancer binding protein alpha 
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CREB  cAMP response element-binding protein 
DBD  DNA binding domain 
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DTT  Dithiothreitol 
EDTA  Ethylenediaminetetraacetic acid 
EMSA  Electrophoretic mobility shift assay 
ER  Estradiol receptor 
ERK  Extracellular signal-regulated kinases 
FAB  French-American-British 
FBS  Fetal Bovine Serum 
FLT3  Fms-related tyrosine kinase 3 
FLT3-ITD FLT3-internal tandem duplication 
FPD  Familial platelet disorder 
G-CSF  Granulocyte colony stimulating factor 
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HAT  Histone acetyl transferase 
HDAC  Histone deacetylase 
HIPK1/2 Homeodomain-interacting protein kinase 1/2 
HSC  Hematopoietic stem cell 
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IL3  Interleukin-3 
IL6  Interleukin-6 
IVT  In vitro transcription-translation 
JAK2  Just another kinase 2 
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PRMT1 Protein arginine methyltransferase 1 
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PTM  Post-translational modifications 
PVDF  Polyvinylidene fluoride 
SCF  Stem cell factor 
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide agarose gel electrophoresis 
SFK  Src family kinases 
SHP2  Src homology tyrosine phosphatase 
STAT3 Signal transduction and activator of transcription 3 
Runx1  Runt-related transcription factor 1 
REP  Repression domain 
TAD  Transactivation domain 
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Molecular and cellular biologist with 15 years of research experience in cancer biology, 
microbiology, immunology and hematopoiesis. Adept at high-content screening, bioassay design 
and execution integrating nanotechnology and robotics; proficient in handling infectious clinical 
samples. Led, supervised and managed cross-disciplinary team-based projects at publicly funded 
institutes and a private start-up biotechnology company. Inventor of high throughput 
miniaturized cellular-based assays in a US patent application. Highly interested in fundamental 
or translational scientific research on the diagnosis and treatments of cancers or infectious 
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2011-2016    Ph.D. candidate, Johns Hopkins University School of Medicine 
(Graduation: May 2016)  Thesis: Transcription factor RUNX1 phosphorylation by SRC favors 
 granulopoiesis 
 Thesis mentor: Alan Friedman, M.D. 
2002-2004  Master of Science (M.Sc.), National University for Singapore 
 Thesis: Molecular characterization of toxins in Clostridium difficile 
 Thesis mentor: Keang-Peng Song, Ph.D. 
1998-2001  Bachelor of Science (B.Sc.), University of Malaya 
 Thesis: Single-stranded Conformation Polymorphism Analysis of  
 Variability of the rpoS sequence in the environmental and clinical  
 isolates of Salmonella typhi 
 Thesis mentors: Kwai-Lin Thong, Ph.D. & Zulqarnain Mohamed, Ph.D. 
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Research and Leadership Experience 
Aug 2012-  Graduate Researcher (Mentor: Alan Friedman, M.D.) 
Present   Johns Hopkins Uni. School of Medicine, Pathobiology Graduate Program 
 Investigate the role of tyrosine phosphorylation of the RUNX1 
transcription factor by Src kinases in the control of granulocyte 
differentiation using biochemical and cell-based functional 
assays. 
Sep 2010-   Senior Research Officer (Advisor: Christopher Wong, Ph.D.) 
July 2011  Genome Institute of Singapore (Singapore)  
 Led and supervised a team of 4 in a large scale siRNA library 
screening set-up to carry out the whole genome human gene 
knockdown functional assay on different cancer cell lines using 
the High Content Screening platform facilitated by an 
automation handling system; the entire system then became 
available to all users at the institute. 
 Validated the Proseek IP-10 Validation Kit from Olink 
Biosciences, who then published the result on their website. 
Aug 2009-   Application Manager in Biology (secondment) 
Aug 2010  Curiox Biosystems Pte. Ltd. (Singapore)  
 Led a team of 3 in the evaluation of the performance of the 
DropArray™ platform using miniaturized high content cell-based 
phenotypic assays on various cell lines. 
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 Led the beta-testing of DropArray™ platform at site of client 
(Sanofi-Aventis, Bridgewater campus NJ, USA). 
 Established the protocols for miniaturized high content cell-
based assays using DropArray™ platform, which were included 
in a US patent application submitted in 2013 (Application No. 
61/711725). 
Sep 2004-   Senior Research Officer (May 2008-July 2009),  
July 2009  Research Assistant (Sep 2004-Apr 2008) 
  (Advisors: Christopher Wong, Ph.D., Lance D. Miller Ph.D. & Kartiki Desai,  
  Ph.D.)  
Genome Institute of Singapore (Singapore) 
 Validated the breast cancer biomarkers identified from a 
comprehensive microarray assay using siRNA knock-down 
functional test and immunohistochemistry staining.   
 Optimized the protocol for NimbleGen microarray-based 
pathogen chip, which was developed as a quick and simple 
diagnostic tool for virus and bacteria pathogen detection from 
clinical samples of Dengue patients, SARS patients and H1N1 
Influenza patients during multiple national and international 
epidemics; the Pathogen Chip technology is now 
commercialized under the company PathGEN Dx Pte. Ltd.   
 
Other Work Experience 
2001   Assistant Nurse 
Ranjoth Singh Obstetric and Gynaecology Specialist Clinic, Ipoh 
 (Malaysia) 
 Assisted doctors and patients during clinic visits; e.g. measured 
blood pressures, prepared diagnostic tests. 
 Facilitated communications between doctors and patients; e.g. 
translated English medical terms to Mandarin or Cantonese, 
explained doctors’ instructions for taking medicines. 
1995   Piano accompanist, City School of Ballet, Ipoh (Malaysia) 
SCIENTIFIC PUBLICATIONS AND PRESENTATIONS 
Peer-Reviewed Journals 
1. WY Leong, H Guo, O Ma, H Huang, AB Cantor, AD Friedman; Runx1 phosphorylation by Src 
increases trans-activation via augmented stability, reduced HDAC binding, and increased DNA 
affinity, and activated Runx1 favors granulopoiesis (2016); Journal of Biological Chemistry, 
291(2): 826-836. 
2. LA Zaritsky, A Dery, WY Leong, L Gama, JE Clements; Tissue specific interferon alpha subtype 
response to SIV infection in brain, spleen and lung (2013); Journal of Interferon & Cytokine 
Research, 33(1): 24-33. 
3. J Zhang, X Liu, A Datta, KR Govindarajan, WL Tam, J Han, J George, CW Wong, K 
Ramnarayanan, TY Phua, WY Leong, YS Chan, N Palanisamy, ET Liu, R Krishna Murthy Karuturi, B 
Lim, LD Miller; RAB11FIP1/RCP is a Novel Breast Cancer Promoting Gene with Ras Activating 
Function (2009); Journal of Clinical Investigation, 119(8): 2171-2183. 
4. WH Lee, CW Wong, WY Leong, LD Miller, WK Sung; LOMA: A Fast Method to Generate 
Efficient Tagged-random Primers despite Amplification Bias of Random PCR on Pathogens 
(2008); BMC Bioinformatics, 9:368. 
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5. CW Wong, CWH Lee, WY Leong, SWL Soh, CB Kartasasmita, EAF Simoes, ML Hibberd, W-K 
Sung & LD Miller; Optimization and Clinical Validation of a Pathogen Detection Microarray 
(2007); Genome Biology, 8:R93. 
Posters 
1. WY Leong, H Guo, O Ma, S Cooper, H Huang, AB Cantor & AD Friedman; Src Activates RUNX1 
in Myeloid Cells to Mediate Granulopoiesis; 10th International Workshop on Molecular Aspects 
of Myeloid Stem Cell Development and Leukemia, Cincinnati, Ohio, USA, 4-7 May 2014. 
2. AD Friedman, WY Leong, H Guo, O Ma, AB Cantor & H Huang; Src Kinase can Activate RUNX1 
Activity via Phosphorylation of C-terminal Tyrosines and Activated RUNX1 Stimulates 
Granulopoiesis; 2013 Meeting of the American Society of Hematology, New Orleans, Louisiana, 
USA, 7-10 Dec 2013. 
3. WY Leong, FL Soh, BL Han, FL Yan, LD Miller & CW Wong; Cell based Assays Suggest Role for 
RAB11F1P1 in Cell Cycle and Apoptosis; American Association for Cancer Research (AACR) 
Annual Meeting 2008, San Diego Conventional Center, San Diego, California, USA, 12-15 Apr 
2008. 
4. CW Wong, CWH Lee, WY Leong, S Soh, ML Hibberd, KW-K Sung, LD Miller; Pathogen 
Detection Microarray – from Lab to Bedside; Keystone Symposia – Respiratory viruses of 
Animals: Causing Disease in Humans, Swissotel the Stamford/Biopolis, Singapore, 10-15 Dec 
2006. 
5. WY Leong, R. Das, KP Song; Molecular characterization and prevalence of Clostridium difficile 
in Singapore; 14th European Congress of Clinical Microbiology & Infectious Disease, Prague, 
Czech Republic,1-4 May 2004. 
6. WY Leong, R. Das, KP Song; Molecular characterization and prevalence of Clostridium difficile 
in Singapore; 7th NUS-NUH Annual Scientific Meeting, National University of Singapore, 30 Sept 
2003.  
Patent 
1. Patent application publication: High throughput miniaturized assay system and methods 
Application number: 14/050, 321; Publication number: US 2014/0235468 A1 
Featured Work 
1. WY Leong, C Wong, M Hibberd, EE Ong; Validation Data for Proseek Assay Development Kit, 




July 2015  Summer Program Teaching Assistant 
   Johns Hopkins University, Krieger School of Arts & Sciences, Department 
   of Biology 
 Taught DNA replication and transcription to 48 freshman and 
advanced pre-college students. 
 Designed learning objectives, assessment activities, examination 
questions. 
 Taught laboratory sessions and demonstrated laboratory 
techniques.   
Sep 2012 –   Graduate Student Teaching Assistant 
Oct 2012  Johns Hopkins University, Pathobiology Graduate Program 
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 Co-designed selected teaching and assessment materials for 
“Mechanisms of Diseases” course. 
 Tutored selected graduate students on the lecture materials. 
2002-2004  Graduate Student Tutor 
National University of Singapore, Faculty of Medicine, Department of  
 Microbiology  
 Taught and assessed 40-50 students in year-round laboratory 
sessions. 
 Tutored approximately 100 students on lecture materials.  
1998   Middle School Science Teacher 
SMJK Ave Maria Convent, Ipoh (Malaysia) 
 Taught multiple sessions of basic science to approximately 200 
students. 
 
AWARDS AND ACCOMPLISHMENTS 
Academic Scholarships and Fellowships 
Aug 2015-   Teaching Fellowship, Johns Hopkins University  
May 2016 Preparing Future Faculty Teaching Academy 
Aug 2011 Margaret Lee Fellowship, Johns Hopkins University School of Medicine  
(1 year full tuition plus stipend) 
July-Aug 2004  Osaka University Frontier Biosciences Summer School Scholarship, 
Japan (7 weeks full tuition plus stipend) 
Internship under supervision of Fumio Hanaoka, Ph.D.  
(Integrated Biology Laboratories, Cellular Biology Group) 
2002-2004  Postgraduate Research Scholarship, National University of Singapore, 
Singapore (2.5 years full tuition and stipend) 
   M.Sc. degree under supervision of Keang-Peng Song, Ph.D.  
(Molecular Pathogenesis Laboratory) 
Academic Awards 
Sep 2015  Winner, Best Oral Presentation, Annual Pathobiology Retreat, Johns  
   Hopkins University School of Medicine 
May 2001  Winner, Best Oral Presentation, MSMBB-Promega Young Researcher 
Award for Molecular Biology Competition, Kuala Lumpur, Malaysia 
2000-2001  Dean’s Award, Faculty of Science, University of Malaya, Kuala Lumpur,  
   Malaysia 
Employment Awards and Nomination 
Nov 2010  Nomination, A*STAR T-UP Excellence Award, Biopolis and Fusionopolis, 
   Singapore(for work on DropArray™ platform with Curiox Biosystems; T- 
   UP denotes “Growing Enterprises with Technology Upgrade”) 
2010   5-year Long-term Service Award, Genome Institute of Singapore (GIS) 
2007, 2006  Sport Award, for serving as committee member of the Recreational  
   Club, GIS 
Music Accomplishments 
2001          Licentiate Diploma in Music, Australia (LMusA) of the Australian Music  
   Examinations Board in Piano Performing 
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1996    Licentiate of the Royal Schools of Music in Piano Performing issued by  
   the Associate Board of the Royal Schools of Music, United Kingdom 
1995    Fellowship Diploma in Pianoforte issued by Trinity College, London 
 
CERTIFICATION AND ADDITIONAL TRAINING 
Certification 
2009-2011 Certification on Competency: Dangerous Goods Regulations for    
  Transporting Infectious Substances and Diagnostic Specimens by Air;   
  World Courier Singapore 
 
Additional training at Johns Hopkins University 
2015  Leadership Module - Project Management, Summer Teaching Institute 
2014  Bootcamp for Technology Entrepreneurs, Science Writing and Communications 
2013  Mouse Pathobiology and Phenotyping  
2012-2013 Research Ethics  
SKILLS 
Areas of Expertise     Languages
Molecular and Cellular Biology         English (fluent) 
Hematopoiesis          Mandarin (fluent) 
Microbiology and Immunology        Cantonese (fluent) 
Infectious Diseases            Malay (proficient) 
Assay Design and Construction 
Instrument Maintenance 
               Genetically Engineered Mouse Model 
               Flow Cytometry (Basic)        
 
 
COMMUNITY SERVICES AND ACTIVITIES (selected) 
May 2015  Volunteer, Civic Works Real Food Farm, Baltimore 
 Transformed vacant lots into community vegetable gardens. 
2013-2014  Organizer, “Ignite Hopkins” storytelling events, JHU School of Medicine 
 Applied for and was awarded a $1,000 grant from JHU Alumni Association. 
2013, 2014  Color Me Rad 5K run, Port to Fort 6K run 
Mar 2013  Volunteer, Maryland Food Bank     
Feb 2013  Interviewer, Recruitment Week, Pathobiology Program, Johns Hopkins Uni. 
2007 - Present Musician, SoundBliss music group, Singapore, www.soundbliss.net 
2006-2009  Committee member, Recreation Club, Genome Institute of Singapore 
2006-2007  Laboratory representative, Genome Institute of Singapore 
 Singapore Science Open House, A*SAR YRAP Scholars Visit & Singapore 
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